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This work summarizes the analysis of two distinct therapeutic approaches for the 
central nervous system (CNS) pathologies, Pelizaeus-Merzbacher disease (PMD) 
and Glioblastoma multiforme (GBM).  
PMD is a severe leukodystrophy that is mainly caused by the overexpression of the 
myelin proteolipid protein (PLP) in oligodendrocytes. Transgenic mice that mimic 
PLP overexpression (Plp-tg) served as a suitable model system to analyze a novel 
therapeutic approach by feeding a ketogenic diet (KD). In this study, KD treatment 
improved pathology in Plp-tg mice. In fact, KD treated Plp-tg mice revealed reduced 
inflammation and decreased lysosomal PLP accumulation with a diminished ER 
stress response. In addition, KD treatment increased oligodendrocyte numbers with 
enhanced myelination and amelioration of the impaired motor phenotype. Moreover, 
KD enhanced ketone body transport and utilization in the CNS, which was 
accompanied by an amelioration of axonal pathology. The present work summarizes 
an innovative therapeutic approach for PMD, in which ketone bodies can be 
integrated into CNS metabolism without the prerequisite of blood-brain barrier (BBB) 
alterations. This approach would provide a major advantage for PMD patients, since 
the status of BBB function is still unknown.   
GBM is highly malignant form of brain tumors, in which standard treatment only 
provided minor impact on patients’ survival. The major challenge in the 
chemotherapy of patients is the application of therapeutically relevant concentrations 
into the brain due to limitation of the BBB. This thesis presents a therapeutic strategy 
that comprises a combined treatment of the cytostatic agent cisplatin with controlled 
manipulation of BBB permeability by isoflurane anesthesia in a GBM mouse model. 
Highlighting the therapeutic benefit of the approach, the combined treatment of 
cisplatin and isoflurane reduced tumor volume and enhanced the immune response 
measured by elevated numbers of T-cell infiltration. In addition tumor viability was 
reduced. The major benefit of our therapeutic approach was the remarkably 
reduction of migrating tumor cells into healthy brain tissue. Therefore, the 
investigated therapeutic strategy for GBM research represents a novel approach to 
target in addition to the tumor center, migrating tumor cells to prevent the tumor from 















4 Ketogenic diet ameliorates disease expression in a mouse model of 
Pelizaeus-Merzbacher disease 
4.1 Introduction 
4.1.1 Central nervous system 
The mammalian central nervous system (CNS) acts as a control center for most of 
the conscious body functions, including movement, thoughts and speech, but also 
sustains homeostasis of body temperature, breathing and heart rate. The CNS 
consists of the brain and spinal cord, which are connected via the brainstem. 
Furthermore, the spinal cord serves as the connection of the brain to the peripheral 
nerves. The blood-brain-barrier (BBB) provides the separation from the CNS and the 
periphery e.g. by regulation of metabolic influx and efflux as well as the protection 
from neurotoxic substances (see chapter BBB 5.1.1). Two types of tissue can be 
found within the CNS: the grey matter, which consists mostly of neurons and 
neuronal cell bodies and the white matter that contains axons. Within the white 
matter, most axons are ensheathed by a lipid-rich multilayered stack of membranes, 
also called the myelin sheath. Glia cells, earlier seen as the “glue” between neurons, 
were shown to be important supporters for neurons and harbor many other functions 
including the adjustment of metabolic homeostasis (Kettenmann and Verkhratsky, 
2011). In the CNS, glia cells outnumber neurons in a ratio of 10 to 1, including 
astrocytes, oligodendrocytes, microglia and endothelial cells. Astrocytes provide 
nutrients to support synapses and axons (Pellerin and Magistretti, 1994; Supplie et 
al., 2017) and help maintaining BBB structure (Abbott et al., 2010). Oligodendrocytes 
are the myelinating glia cells in the CNS, but also provide direct metabolic support 
for the axon (e.g. lactate, pyruvate) (Fünfschilling et al., 2012; Hirrlinger and Nave, 
2014). Microglia are immune system cells, acting as the primary immune response 
of the CNS and further show phagocytic function to clear cell debris. Endothelial cells 
provide the lining of the cerebral blood vessel. Tightly connected to each other, they 





4.1.2 Brain energy metabolism 
Since the mammalian brain volume and complexity increased during development, 
efficient energy metabolism became fundamental. The human brain energy 
consumptions accounts for 20% of the total ATP production. All cells of the CNS are 
able to produce and use energy in form of ATP.  
4.1.2.1 Glucose metabolism  
Glucose, as the primary energy source of the brain, enters the CNS through glucose 
transporters. The expression of glucose transporters is diverse throughout cells 
types. The most important glucose transporter, GLUT1, is mainly expressed by 
astrocytes and endothelial cells, whereas GLUT3 and GLUT5 by neurons and 
microglia, respectively. (Vannucci et al., 1997; Zhang et al., 2014). Once entering the 
cell, glucose gets phosphorylated by hexokinase to form glucose-6-phophate. 
Glucose-6-phosphate can then be used in four main different ways: (1) as an energy 
depot in form of glycogen (2) for the pentose-phosphate pathway to produce NADPH 
by building DNA or RNA (3) for energy demands during cytoplasmic glycolysis, which 
produces two pyruvate molecules and lactate without the need of oxygen (4) 
glycolysis followed by transportation of glycolytic end products into mitochondria, 
where the tricarboxylic acid (TCA) cycle and oxidative phosphorylation takes place 
to produce ATP under oxygen consuming conditions. Furthermore, not only in terms 
of oxygen shortage, glycolysis derived pyruvate as well as lactate can be shuttled 
out of the cell via monocarboxylate transporters (MCT) to provide metabolic coupling 
to neighboring cells e.g. axons. This process, called the “lactate shuttle”, was first 
described from astrocytes to axons, but later it has been postulated that also 
oligodendrocytes can supply the axon with lactate (Figure 4.1) (Fünfschilling et al., 






Figure 4.1I Model of neuronal metabolic support by oligodendrocytes. Glucose as the main 
fuel of the CNS is imported in oligodendrocytes via glucose transporter 1 (GLUT1) or through 
astrocytic connexins (CX) and gets integrated in glycolysis. Glycolysis derived lactate and 
pyruvate can be used in the tricarboxylic acid (TCA) cycle and oxidative phosphorylation (COX) 
for local adenosine triphosphate (ATP) production or upon axonal energy requirements they can 
be shuttled into the axon through the action of monocarboxylate transporters (MCT1,2) (taken 
from Fünfschilling et al., 2012).  
 
4.1.2.2 Fatty acid metabolism 
Already in the early 70th it was shown that fatty acids are able to enter the CNS 
(Dhopeshwarkar et al., 1971; Dhopeshwarkar and Mead, 1970, 1969). Fatty acids 
are actively transported via fatty acid transport proteins (FATPs) with FATP-1 and 
FATP-4 as the most abundant ones expressed in mice and human (Mitchell et al., 
2011). 
Besides glucose metabolism, the brain readily adapts to different metabolic 
conditions, by using circulating fatty acids for β-oxidation to comply energetic needs 
in the adult brain (Ebert et al., 2003; Romano et al., 2017). Once imported into the 
cytosol, fatty acids get activated via the fatty acyl-CoA synthetase to acyl-CoA and 
transported with a carnitine carrier system first into the outer mitochondrial 
membrane (carnitine palmitoyltransferase I (CPT-I)) followed by the inner (carnitine 
palmitoyltransferase II (CPT-II)), where the β-oxidation occurs. During β-oxidation, 
acyl-CoA is converted in a four step enzyme cascade to acetyl-CoA, which can 
directly be used in the TCA cycle or utilized in a reversed mechanism to build up fatty 




transport of acyl-CoA into the outer mitochondrial membrane by the CPT-I, harbors 
a feedback loop by allosteric inhibition with malonyl-CoA, an intermediate in fatty acid 
synthesis.  
 
4.1.3 Fatty acid and cholesterol synthesis 
Despite the use of fatty acids as an energy source, the more common purpose is the 
synthesis of CNS sterols for the integration in membrane structures, especially 
myelin. Since the periphery is shielded from the CNS via the BBB, nutritional lipids 
enter the brain only in a limited manner. For example, phytosterols only account for 
>1% of adult CNS lipids (Jansen et al., 2006; Vanmierlo et al., 2012). Further it was 
shown that lipoproteins containing ApoE, the main carrier for cholesterol, are not able 
to enter the CNS (Linton et al., 1991). 
The synthesis of fatty acids reached the highest capacity during myelination. Fatty 
acid synthesis takes place within the cytosol of the cell and includes a six-step 
mechanism. The rate limiting enzyme is acetyl-CoA carboxylase (ACC1) that 
converts acetyl-CoA into malonyl-CoA. In addition fatty acid synthases (FASN) 
catalyze the elongation of the fatty acid chain upon it reached the required carbon 
chain length. The chain length are classified in short-chain (<6 carbons), medium-
chain (6-12 carbons), long chain (13-21 carbons), and very long-chain fatty acids 
(>21 carbons).  
In the CNS cholesterol is synthesized locally by neurons and glia cells (Björkhem et 
al., 2004) (Figure 4.2). During myelination, mainly oligodendrocytes synthesize 
cholesterol. For cholesterol homeostasis, it has been claimed that astrocytes are the 
major source of CNS cholesterol (Pfrieger and Ungerer, 2011). Cholesterol 
homeostasis is highly regulated in the CNS, since blood-brain-barrier impairment 
increased both directions, import and export of cholesterol equally (Saeed et al., 
2014). In the brain cholesterol is transported via lipoproteins, with the predominant 
one apolipoprotein E (ApoE). Import and export of ApoE bound cholesterol between 
different cell types of the brain is mediated via ATP-binding cassette (ABC) 
transporters (e.g. ABCA1, ABCG1) (Kim et al., 2008) and lipoprotein transporters 





Figure 4.2I Cholesterol metabolism in the CNS. Since cholesterol is unable to cross the BBB, 
it is mainly synthesized locally in the CNS. All glia cells and neurons are able to synthesize 
cholesterol with 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) as the rate-limiting 
enzyme. The expression of HMGCR is highly regulated by the transcription factor SREBP (sterol 
regulatory element-binding protein). In oligodendrocytes, cholesterol binds to proteolipid protein 
prior to the integration into the myelin sheath. ABC transporter (ABCA1) generate apolipoprotein 
E (ApoE) containing lipoproteins, the main cholesterol carrier within the CNS. Furthermore, 
cholesterol is highly reutilized with low-density lipoprotein receptors (LDL-R) responsible for 
endocytosis in oligodendrocytes and neurons. One major cholesterol excretion route is the 
hydroxylation to 24(S)-hydroxycholesterol (24-OHC) by cholesterol 24-hydroxylase (CYP46), but 
also another transport system has been postulated including ApoE (Xu, 2006) (modified from 
Saher and Stumpf, 2015). 
 
The brain is able to turnover cholesterol to 24-hydroxycholesterol for excretion 
through the blood-brain-barrier and elimination by the bile. This step is catalyzed by 
the P450 enzyme (Cyp46a1), which was supposed to be mainly expressed in 
neurons (Lund et al., 1999; Smith et al., 1972), but new data revealed that further 
astrocytes and oligodendrocytes show a high expression (Zhang et al., 2014). 
Approximately two-thirds of brain cholesterol is excreted via this mechanism. The 
remaining third are supposed to be excretes through another pathway, which might 
involve of ApoE function (Saher and Stumpf, 2015; Xu, 2006).  
 
4.1.4 Myelin 
Highlighting the role of CNS sterols, one of the most important structure that is built 




consumes high amounts of axonal energy. Myelin, with its unique lipid composition 
increases membrane resistance and supports the axon with the insulation of a 
multilayered membrane stack. Axonal segments that are enclosed by myelin 
membranes comprises the internode, the adjacent juxtaparanodal region and the 
paranode. Myelin loops are anchored at the paranodes. The unmyelinated region 
between each axonal myelin segment are called nodes of Ranvier, which are highly 
enriched in voltage-gated sodium channels. These complex molecular organization 
allows rapid salutatory conduction of action potentials.  
During myelination the newly formed myelin sheath is first assembled close to the 
axons inner tongue, followed by several wrapping steps from the inside to the outside 
(Snaidero et al., 2014) and later the compaction of the layers is achieved with the 
involvement of myelin proteins. The myelin sheath shows alternating structures of 
electron-dense and electron light layer, representing the major and minor dense lines 
inclosing cytoplasmic areas. The minor dense line is also called intraperiod line, since 
it displays the association of two myelin layers (Baumann and Pham-Dinh, 2001). 
The g-ratio, calculated by the ratio of fiber diameter divided by axon diameter, is a 
measure of myelin thickness for optimal conduction velocity. The optimum of 
conduction velocity was calculated as the g-ratio of 0.6-0.7, but further up to 0.8 was 
shown to provide effective insulation properties (Waxman, 1980).  
4.1.4.1 Myelin lipids 
CNS myelin contains high amounts of lipids with a dry weight of about 70%, including 
glycolipids (31%) and cholesterol (26%) (Chrast et al., 2011). The main components 
of myelin; cholesterol, phospholipids and glycosphingolipids are integrated in the 
myelin membrane in the ratio of 2:2:1 (O’Brien and Sampson, 1965). For cholesterol 
it was shown to be essential for myelin formation (Saher et al., 2005). Furthermore, 
myelin lipid and protein composition is highly conserved throughout species with an 
estimation of about 80% similarity between mice and humans (Gopalakrishnan et al., 
2013). Despite the fact, that myelin lipids are important to sustain membrane fluidity, 
major interest focus on their role in distinctive membrane complexes, called 
membrane lipid rafts. Sphingolipids, cholesterol, and membrane proteins were 
shown to form these platforms to function in protein sorting, trafficking and signal 




4.1.4.2 Myelin-associated proteins 
In addition to lipids, the myelin membrane contains different proteins, listed in 
descending order of abundance:  MOG, MAG, CNP, MBP and PLP. The molecular 
function of the myelin oligodendrocyte glycoprotein (MOG) is so far unknown and it 
is of minor abundance in myelin (1%). It has been speculated, that it might be 
involved in the regulation of oligodendrocyte microtubule stability or in providing 
structural integrity by interacting with the cytoskeleton. Furthermore, it might support 
communication between myelin and the immune system (Johns and Bernard, 1999). 
Myelin-associated glycoprotein (MAG) belongs to the immunoglobulin superfamily 
and has with relatively low abundance (1%) in myelin. It is located at the periaxonal 
membrane along the inner myelin sheath, which emerged the assumption that MAG 
might function in axo-glia interaction (Martini and Schachner, 1988). Nevertheless, 
MAG-deficient mice only showed a minor delay in myelination, suggesting a 
compensatory mechanism (Montag et al., 1994). The biological function of the 
membrane interacting protein, 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP) 
remains so far elusive, since the substrate of the CNP enzyme is not located within 
the CNS. However, analysis of CNP knockout mice revealed normal myelin structure, 
but they develop severe axonal swellings resulting in axonal degeneration (Lappe-
Siefke et al., 2003). These findings indicate a role of CNP in axo-glia support and 
axonal integrity. Myelin basic protein (MBP) constitutes with 8% as the second most 
abundant one in the CNS (Jahn et al., 2009). MBP functions in the adhesion of the 
different layers of the compact myelin. Furthermore MBP deficiency in mice led to 
the severely dysmyelinated phenotype of the “shiverer mouse”, with tremors, ataxia 
and acute seizures (Roach et al., 1983).   
 
4.1.4.2.1 Proteolipid protein (PLP) 
The PLP1 gene encodes for proteolipid protein, which consists of 277 amino acids 
(30 kDa) and constitutes with ~17% the most abundant myelin protein in the CNS in 
mice (Jahn et al., 2009). PLP is a transmembrane protein of the myelin sheath, which 
upon splicing generates the 35bp smaller isoform DM20. PLP contains one 
intracellular and two extracellular loop regions. Both, the N- and the C-terminus 




disulfide bridges. Mutations disrupting these connections were shown to induce PLP 
endoplasmic reticulum (ER) retention and trigger the unfolded protein response 
(UPR) (Dhaunchak and Nave, 2007).  PLP1 is predominantly expressed in 
oligodendrocytes, especially during myelination. PLP protein synthesis takes place 
in the ER, in which PLP associates with cholesterol and is incorporated in membrane 
lipid raft domains in the secretory path (Krämer-Albers et al., 2006; Simons et al., 
2000). After vesicular transport to the plasma membrane, PLP is finally integrated 
into the developing myelin sheath (Nussbaum and Roussel, 1983; Simons et al., 
2000). PLP-deficient mice exhibit reduced cholesterol content in myelin membranes, 
highlighting the function of PLP in the enrichment of myelin cholesterol (Werner et 
al., 2013). Moreover, PLP-deficient mice show a condensed intraperiod line with 
reduced axonal conduction velocity, indicating that the extracellular structures of PLP 
function as a spacer between the single myelin layers (Boison and Stoffel, 1994). 
Furthermore, adult Plp1 knock-out mice exhibit severe axonal swellings resulting in 
axonal degeneration (Klugmann et al., 1997). It has been postulated that PLP 
functions in the maintenance of axonal integrity (Garbern et al., 2002). Insight in PLP 
function to provide axonal integrity might be given by the finding that reduced N-
acetyl-aspartate (NAA) levels were found in PLP-deficient mice and PMD patients 
(Garbern et al., 2002). NAA is synthesized in neuronal mitochondria and degraded 
by the enzyme aspartoacylase (ASPA), which is mainly expressed in 
oligodendrocytes. It has been postulated that neuronal-derived NAA is shuttled into 
oligodendrocytes to increase the expression of pro-myelination factors e.g. 
sphingomyelin synthesis (Singhal et al., 2017). A decreased level of NAA might 
indicate impaired axon-glia communication, which can affect axonal integrity.  
Mutations, overexpression or loss of the PLP1 gene (chromosome Xq22.2) cause 
the leukodystrophy Pelizaeus-Merzbacher Disease or the milder variant Spastic 
Paraplegia Type 2, respectively 
 
4.1.5 Pelizaeus-Merzbacher Disease (PMD)  
PMD is a severe and fatal leukodystrophy that currently lacks any therapeutic option. 
The incidence of PMD varies depending on demographic factors and ranges 
between 90.000 and 750.000 (Hobson and Kamholz, 1999). Typically men are 




X-chromosome.  The symptoms of PMD include delayed motor and intellectual skills 
as well as tremor and spasticity. Furthermore, patients suffer from reduced white 
matter in the brain investigated by magnet resonance imaging (Wang et al., 1995). 
The clinical outcome of PMD varies from connatal severe forms with life expectancy 
of a few years to very mild PMD variants, such as Spastic Paraplegia Type 2 (SPG2). 
SPG2 is caused by deletion of the PLP1 gene, and patients have a relatively normal 
life expectancy. Therefore, PMD pathology is rather caused by a “gain-of-function” 
effect than “loss-of-function”, due to toxic accumulation of mutated or native PLP 
protein. Connatal forms of PMD are caused by a number of missense mutations or 
triplication of PLP1, whereas PLP1 gene duplication accounts for the most common 
form of PMD, named classical PMD (Figure 4.3). Patients with classical PMD usually 
start to have symptoms within the first year of life and often fail to develop motor 
abilities, cognition and speech. With constant care, physiotherapy and slowed 
disease progression in adulthood, their survival extends often until the sixths decade 
(Woodward, 2008).  
 
 
Figure 4.3I Classification of PMD according to clinical severity. The most severe cases of 
PMD (Pelizaeus-Merzbacher disease) are summarized by the term connatal PMD, which 
comprises highly increased PLP1 dosages and severe missense mutation. The classical PMD 
that represents the most common form, includes PLP1 duplication as well as mild missense 
mutations. Spastic paraplegia type 2 (SP2) describes the mildest form of PMD, which comprises 
null mutations, but also modest increase in gene dosage or mutations with unaffected PLP 
function (adapted from Yamamoto and Shimojima, 2013).  
 
4.1.5.1 Mouse models of PMD 
To date several mouse models mimicking diverse states of PMD pathology have 
been generated with distinct characteristics regarding the impact on oligodendrocyte 




accomplish relatively normal myelin formation, but later they develop myelin 
outfoldings and highly severe axonal impairments (Boison and Stoffel, 1994; 
Klugmann et al., 1997). Mouse models for the most severe clinical outcome, the 
congenital PMD, include the naturally occurring jimpy and rumpshaker mouse lines. 
Jimpy Plp1 contains a 74-nucleotide deletion in Plp1 mRNA, resulting in a frameshift 
that causes the lack of the fourth PLP transmembrane domain (Nave et al., 1987, 
1986). The milder rumpshaker Plp1 mutant shows an amino acid substitution 
(Ile186Thr) (Griffiths et al., 1990). It was shown that PLP is a cholesterol binding 
protein mislocalized in Plp1 transgenic and Plp1 mutant mice (Krämer-Albers et al., 
2006; Simons et al., 2002). PLP/DM20 misfolding, retention, missorting, and toxicity 
are relevant PMD disease mechanisms (Dhaunchak and Nave, 2007; Dhaunchak et 
al., 2011; Schneider et al., 1995) that apply to overexpressed PLP as well as PLP 
mutants. Toxicity is caused by accumulation of mutant as well as high amounts of 
native PLP protein, which leads to e.g. impaired trafficking of PLP and cholesterol to 
the plasma membrane (Saher et al., 2012).   
The PLP jimpy mutant gets misfolded and retained in the ER provoking a strong 
unfolded protein response and ER stress (Gow et al., 1998, 1994; Swanton et al., 
2005), whereas some rumpshaker PLP reaches the plasma membrane, also 
correlating with its residual ability to associate with cholesterol (Krämer-Albers et al., 
2006). These results are supported by the finding that in PMD mutant mice the ER 
stress response correlates with the disease state (Southwood et al., 2002). Mouse 
models for Plp1 overexpression include the Plp-tg66/66 (seven copies) and Plp-tg72/72 
(three copies) mouse lines (Readhead et al., 1994) as well as the Plp (+ four copies) 
and Plp (+ two copies) mouse lines (Kagawa et al., 1994). The number of integrated 
transgene copies reflects disease progression including myelination state, 
oligodendrocyte and axonal loss as well as life expectancy, which is comparable to 
patients (Wolf et al., 2005).  
4.1.5.1.1 Plp-tg72/72 mouse line  
During this study the Plp1-tg72/72 transgenic mouse was used, which contains three 
copies of the Plp1 transgene (Readhead et al., 1994). Plp1-tg72/72 provides an 
accurate mouse model for classical PMD, since Plp1 overexpression reflects a two-
fold increase in protein abundance, which is comparable to PMD patients. The mice 




brain. Together with strong inflammatory responses and oligodendrocyte loss these 
mice develop axonal degeneration (Readhead et al., 1994). On the behavioral level 
the mice exhibit severe motor impairments and acute seizures (Edgar et al., 2010; 
Karim et al., 2010). In Plp1-transgenic oligodendrocytes it was shown that PLP 
overexpression causes the accumulation of PLP and cholesterol in the late 
endosome/ lysosome, which leads to decreased levels of plasma membrane 
cholesterol (Saher et al., 2012; Simons et al., 2002). In a treatment approach, 
supplementation of dietary cholesterol rescued the PMD pathology in Plp1-tg72/72 
mice (Saher et al., 2012). The mice showed an increase in myelin content in optic 
nerve and spinal cord. Furthermore, cholesterol treatment reduced intracellular 
PLP/cholesterol accumulation in mutant oligodendrocytes, and secondary 
inflammation as well as motor defects were restored. A compromised blood-brain 
barrier of mutants served as prerequisite for the treatment approach, since 
cholesterol, which is normally shielded from the CNS, entered the brain and improved 
the balance between PLP and cholesterol. In two other studies, it was shown that 
curcumin treatment decreased oxidative stress levels and inflammation in Plp-tg 
mice by lowering glutathione levels and Lonaprisan administration (progesterone 
antagonist) targeted Plp1 mRNA expression thereby decreasing the level of Plp1 
from 1.8 to 1.5 fold in brain tissue (Epplen et al., 2015; Prukop et al., 2014). 
 
4.1.6 Ketogenic diet 
The ketogenic diet (KD) is based on a ratio of high fat, low carbohydrates and 
sufficient protein, to reprogram the body to metabolize fats for energy requirements 
instead of carbohydrates. Ketone bodies are comprised by three compounds: β-
hydroxybutyrate, acetoacetate and acetone, with the latter being less important as 
energy source. Ketone bodies are produced by fatty acid oxidation in the liver. They 
can enter the CNS via monocarboxylate transporters (MCT) and be integrated in 






Figure 4.4I Model of metabolic support of ketone bodies. Fatty acids in the blood stream enter 
the liver and are converted to ketone bodies by fatty acid oxidation. The conversion of fatty acids 
into acetoacetate requires the enzyme 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2). 
Ketone bodies can be transported by monocarboxylate transporters (MCT1,2 or 7). The three 
enzymes involved in ketolysis are 3-hydroxybutyrate dehydrogenase 1 (BDH1), 3-oxoacid CoA-
transferase 1 (OXCT1) and acetyl-coA acetyltransferase 1 (ACAT1) leading finally to acetyl-CoA 
production. Acetyl-CoA can be used in the tricarboxylic acid (TCA) cycle or to build-up fatty acids 
and cholesterol involving the following selected enzymes: 3-hydroxy-3-methylglutaryl-CoA 
synthase 1 (HMGCS1), 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), farnesyl-
diphosphate farnesyltransferase also referred to as squalene synthase (FDFT1), acetyl-CoA-
carboxylase (ACC1), fatty acid synthases (FASN β-hydroxybutyrate dehydrogenase 1. 
 
MCT1 is mainly expressed by astrocytes and endothelial cells. Whereas MCT2 was 
predominantly expressed by neurons, but also oligodendrocytes and microglia 
revealed MCT2 expression (Pellerin et al., 2005; Zhang et al., 2014). Once ketone 
bodies were imported into cells of the CNS, BDH1 interconverts β-hydroxybutyrate 
to acetoacetate. OXCT1, the rate-limiting enzyme of ketolysis, converts acetoacetate 
to aceto-acetyl-CoA. ACAT1 facilitated the reaction of aceto-acetyl-CoA to two 
molecules of acetyl-CoA. Acetyl-CoA can be used for example as energy source in 
the TCA cycle or utilized to synthesize fatty acids or cholesterol, but further many 
other metabolic pathways of acetyl-CoA are possible. In newborn rodents, which rely 




of the brains energy requirements (Cremer, 1982). This proportion decreases 
drastically after weaning, which might reflect reduced activity of the main enzymes 
for ketone body lysis, BDH1 (β-hydroxybutyrate dehydrogenase 1), OXCT1 (3-
oxoacid CoA-transferase 1) and ACAT1 (acetyl-CoA acetyltransferase 1). (Krebs et 
al., 1971). It was shown that in young rodents, ketone bodies are used to synthesize 
lipids and especially cholesterol, which is predominantly integrated in the myelin 
sheath (Koper et al., 1981). Furthermore, ketone bodies as metabolites were proven 
to be the main supplier of lipid and cholesterol synthesis, even in the presence of 
sufficient glucose (Webber and Edmond, 1977). A benefit for lipid synthesis by 
ketone bodies compared to glucose might be that aceto-acetyl-CoA, which is 
produced during ketolysis can be directly integrated in fatty acid synthesis. In contrast 
glycolytic derived acetyl-CoA must first be converted to aceto-acetyl-CoA (Morris, 
2005).  
 
4.1.6.1 Treatment potential of the ketogenic diet 
In the early 1920s the ketogenic diet was developed and first applied in the treatment 
of epilepsy (Liu et al., 2018). Since then, researchers in a broad field of neurological 
related diseases discovered the potential of the ketogenic diet, but so far little is 
known about the function of KD. Hereafter, I summarize interesting findings providing 
insight in the neuroprotective role of ketone bodies 
Treatment of KD in epilepsy provided anticonvulsant and anti-epileptogenic 
properties (Liu et al., 2018). In a clinical treatment trial of childhood epilepsy with KD 
it was shown that two-third of the children treated with KD had a seizure reduction of 
50-90% (Neal et al., 2008). Direct mechanistic insight of KD action in epilepsy and 
seizure control is unknown, but it has been speculated that a combination of 
enhanced ketosis, reduced glycolysis and increased amounts of fatty acids leads to 
a metabolic switch which induces neuroprotection. Mechanisms that might be 
involved in KD neuroprotection include an increase in oxidative phosphorylation and 
enhanced mitochondrial biogenesis which can causes reduction of reactive oxygen 
species (ROS) (Bough and Rho, 2007). Furthermore, impact of KD function on the 
reduction of mitochondrial oxidative stress release might be provided by the fact that 
elevated amounts of fatty acids induce the expression of mitochondrial uncoupling 




upregulation of mitochondria biogenesis, control of calcium flux and reduce free 
radical formation (Andrews et al., 2005). The results are supported by KD fed mice, 
which showed increased abundance of cerebral UCPs associated with reduced ROS 
levels (Sullivan et al., 2004). Moreover, KD treatment has been postulated to 
ameliorate mitochondrial dysfunction. In a therapeutic approach, mice treated with 
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), which blocks mitochondrial 
complex I of the electron transport chain, were supplied with D-β-hydroxybutyrate 
infusion (Abou-Sleiman et al., 2006). Interestingly, neurons of D-β-hydroxybutyrate 
treated mice were protected from the neurotoxin. Further in vivo studies in cultured 
neurons provided evidence that D-β-hydroxybutyrate functions by elevating oxidative 
phosphorylation of mitochondria in a complex II dependent manner (Tieu et al., 
2003). Besides the neuroprotective function of KD, another study provided insight in 
the anti-inflammatory role of ketone bodies by decreasing pro-inflammatory 
cytokines (Yang and Cheng, 2010).  
In summary, KD provided anticonvulsant and anti-inflammatory properties, increased 
oxidative phosphorylation and reduced oxidative stress in mitochondria. 
Furthermore, the metabolic switch induced by KD treatment might enhance 
myelination due to fact that ketone bodies are predominantly used for the synthesis 
of fatty acids and especially cholesterol (Webber and Edmond, 1977). These findings 
could be of great interest for the treatment of neurodegenerative diseases associated 
with hypomyelination and mitochondrial malfunctions such as PMD.  
 
4.1.7 Aim of the study 
PMD is a fatal leukodystrophy with a lack of efficient therapeutic options. A previous 
therapeutic approach used the compromised blood-brain barrier of mutant Plp1-
tg72/72 mice for dietary cholesterol supplementation, which rescued PMD pathology 
(Saher et al., 2012). 
The aim of this study was to analyze a new treatment approach of the Plp1-tg72/72 
mice by feeding a ketogenic diet to support endogenous CNS lipid homeostasis 
independent of blood-brain barrier alterations, since it is unknown whether PMD 
patients suffer from increased permeability. Our experimental design was based on 
the fact that ketone bodies are predominantly used for the synthesis of fatty acids 




tg72/72 mice, since an increase in local abundance of cholesterol together with fatty 
acids might further enhance myelin synthesis. In addition, all glia cells and neurons 
of the central nervous system can take up ketone bodies and utilize them as 
metabolites. Due to the severe loss of oligodendrocytes in Plp-tg72/72 mice, 
oligodendrocytic support of axons is highly impaired. Therefore, we hypothesized 
that increased ketone body utilization might provide a direct or indirect support for 
axons to cover their local energy requirements.  
In this study, ketogenic diet (KD) was fed from 2 until 12 weeks of age to investigate 
the impact on inflammation, oligodendrocyte numbers, myelination, axonal pathology 
and motor phenotype of PLP-tg72/72 mice. Furthermore, metabolic changes in spinal 
cord tissue of PLP-tg72/72 mice caused by stimulated ketone body metabolism were 
analyzed.  
With our experimental approach we wanted to address the questions whether KD (1) 
can reduce CNS inflammation (2) increases oligodendrocyte numbers (3) enhances 
myelination (4) ameliorates the affected motor phenotype (5) alters ketone body and 
accordingly glucose metabolism within the CNS (6) decreases ER and lysosomal 



























4.2.1 Phenotypical change of Plp-tg mice 
Classical Pelizaeus-Merzbacher disease (PMD) is a severe leukodystrophy that is 
mainly caused by increased gene dosage of the myelin protein PLP1. For this study 
the Plp1 transgenic mouse line 72 (Readhead et al., 1994), which harbor three copies 
of the Plp1 gene resulting in an about two-fold overexpression, was used. These 
mice are further referred to as Plp-tg mice. In a novel therapeutic approach, it was 
possible to ameliorate disease severity in the transgenic mouse model by feeding a 
high cholesterol diet (Saher et al., 2012). Cholesterol in the circulation was able to 
pass the BBB, due to compromised BBB function.  
The original aim of this study was to further define the potential of dietary cholesterol 
as a treatment option of PMD, but unexpectedly Plp-tg mice developed changes in 
pathology. In 2014, the entire mouse colony suffered from a wide-spread infection of 
mites and helminthes, which was treated with the standard treatment MiteArrest, 
Fenbendazol and Ivermectin. Despite the successful elimination of the infection, this 
treatment also strongly reduced breeding performance and diminished early 
postnatal survival of litters. Moreover, routinely monitored Plp-tg mice on standard 
diet after termination of the anti-infective treatment (further referred to as Plp-tg 2014) 
had improved in some features typical for PMD pathology. The newly patho-
phenotype showed increased mean body weight reaching wildtype levels (23.1±0.4g 
body weight in 2012 prior to infection compared to 26.1±0.7 in 2014 after treatment). 
Backcrossing the line on the C57BL6/N genetic background (Plp-tg 2015) did not re-
establish the previously observed reduced body weight (Figure 4.5a). Plp-tg mice as 
well as PMD patient suffer from acute seizures and impaired motor function (Edgar 
et al., 2010; Karim et al., 2010; Saher et al., 2012). Therefore, the altered patho-
phenotype was further characterized by the elevated beam test which assesses 
motor coordination and balance. Mice walk on an elevated narrow beam into a save 
box. The number of paw slips that occur during this process is quantified. In 
accordance with the normalized body weight, Plp-tg mice in 2014 showed 
significantly improved motor function when compared to cohorts from 2012 (Figure 
4.5b). Gliosis and inflammation are also hallmarks of PMD pathology in patients and 





Figure 4.5| Plp-tg mice developed phenotypical changes. (a) Body weight at twelve weeks of 
age of non-transgenic wildtype, Plp-tg mice in 2012, 2014 and after backcross in 2015. One-way-
ANOVA with Tukey’s multiple comparison test was performed. (b) Motor performance assessed 
by the elevated beam test comparing the number of slips between non-transgenic wildtype (n=8), 
untreated Plp-tg mice in 2012 (n=19) and in 2014 (n=12). Two-way-ANOVA with Bonferroni’s post 
test revealed significant differences between Plp-tg mice in 2012 and 2014. (c) Histological 
evaluation of wildtype controls and Plp-tg mice in 2012 and 2014, showing the number of activated 
microglia/macrophages (MAC3) (n=4-6), and reactive astrocytes (GFAP) (n=4-11) in the CST, 
and CD3+ T cells (n=4-6) in the dorsal white matter of the spinal cord. Three sections per animal 
were staining for quantification. One-way-ANOVA followed by Tukey’s multiple comparison test 
in 2012 compared to mice from the 2012. (d) G-ratio analysis in the CST of non-transgenic 
wildtype compared with untreated Plp-tg versus treated mice (5% cholesterol supplementation to 
standard chow) assessed in 2012 (n=3-5) and 2014 (n=3-5). Student’s t-test was performed on 
the g-ratio measurement of Plp-tg mice in 2014 in comparison to 2012. (e) Evans Blue 
extravasation assay for the measurement of BBB permeability in non-transgenic wildtype mice 
(n=6) compared to Plp-tg in 2014 (n=3). ApoE KO (n=4) mice served as positive control. One-
way-ANOVA with Tukey’s multiple comparison test. Differences were considered significant with 





To determine whether also reduced inflammation contributed to the ameliorated 
phenotype, Plp-tg mice at the age of 12 weeks were re-evaluated histologically. Plp-
tg mice in 2014 improved in all tested parameters in comparison to previous cohorts, 
showing strongly diminished microgliosis (MAC3+), astrogliosis (GFAP+) and T-cell 
infiltration (CD3+) (Figure 4.5c). 
It is conceivable that the infection as well as the anti-mite/helminths treatment 
favored the selection of the fittest Plp-tg mice, but also an unspecific genetic drift 
could explain the improved phenotype of untreated Plp-tg mice. Particularly, loss of 
one transgene copy could have led to less severe Plp1 overexpression, leading to 
the ameliorated disease expression in Plp-tg mice. Therefore, the level of Plp1 
mRNA overexpression in brain lysates was determined at the age of 13 weeks. In 
the brain of Plp-tg mice, a 1.8-fold overexpression of PLP was detectable in 2016 
(Dr. Theresa Kungl, Dr. Thomas Prukop personal communication), which is in 
accordance with published data (Prukop et al., 2014), indicating unaltered genetic 
expression of Plp1 in 13 weeks old mice. 
The primary defect of Plp-tg mice is the severe hypomyelination. Therefore, the 
thickness of myelin sheaths was assessed by g-ratio analysis of the corticospinal 
tract (CST) in wildtype and Plp-tg (Figure 4.5d). Reflecting the overall ameliorated 
pathology pf Plp-tg mice in 2014, hypomyelination of Plp-tg slightly but significantly 
improved. Previously, a remarkable therapeutic benefit was observed by feeding a 
cholesterol-rich diet to Plp-tg mice that reached g-ratio levels comparable to wildtype 
mice (Saher et al., 2012). When testing the efficacy of dietary cholesterol 
supplementation on myelin thickness in the Plp-tg mouse line from 2014, Plp-tg mice 
significantly increased myelination in response to cholesterol as before; however, the 
degree of amelioration was strongly reduced compared to cohorts from 2012 (Figure 
4.5d). 
The impairment of the BBB is a prerequisite for peripheral cholesterol to enter the 
CNS and to ameliorate pathology in Plp-tg mice (Saher et al., 2012). To address the 
question, whether changes in BBB integrity contributed to the observed reduction in 
treatment efficacy of dietary cholesterol, the permeability of Plp-tg mice was 
quantified as described previously (Berghoff et al., 2017a). However, when 
measuring Evans blue extravasation in brain lysates, Plp-tg mice showed increased 
permeability of the BBB (Figure 4.5e) to a degree which is comparable to ApoE null 




BBB properties do not account for the altered treatment efficacy of dietary cholesterol 
supplementation. 
 
4.2.2 Development of new treatment strategies in Plp-tg mice 
Ketone bodies were shown to be predominantly used for the synthesis of fatty acids 
and especially cholesterol, even in the presence of high glucose (Webber and 
Edmond, 1977). This preference could lead to a benefit for Plp-tg mice, since they 
exhibit severe hypomyelination and an increase local abundance of fatty acids and 
cholesterol might enhance myelin synthesis. Therefore, we decided to test a new 
treatment approach, by feeding other lipid based diets to Plp-tg mice. High fat diets 
increase the abundance of free fatty acids in the blood stream, which are converted 
by the liver to ketone bodies. Endothelial cells at the BBB express monocarboxylate 
transporter 1 (MCT1) which mediates the transport of ketone bodies across the BBB. 
In the CNS, glia cells and neurons express different MCTs for the import of ketone 
bodies (or others e.g. lactate) to use them as an energy source. The advantage of 
ketone bodies to be directly transported across the BBB provides the main benefit 
for PMD patients, since it is unknown whether PMD patients suffer from increased 




Figure 4.6| Treatment paradigm for lipid supplementation. (a) Composition of standard chow 
(SD), medium chain fatty acid diet (MCT) and classical ketogenic diet (KD). (b) Treatment scheme 
showing the treatment duration either with SD, MCT or KD. Additionally, time points of rotarod 





For our treatment studies we decided to use the following diets: standard diet (SD, 
11% fat), medium chain triglyceride diet (MCT, modified Surwit with 43% fat content) 
and classical ketogenic diet (KD, ketogenic diet with 80% fat content) (Figure 4.6a). 
Young mice during lactating phase highly express important enzymes for ketone 
body utilization (Krebs et al., 1971). To prevent the naturally occurring switch from 
ketone body usage to mainly glucose metabolism, ketogenic diet was provided 
already during lactating phase at two weeks of age until endpoint analysis with twelve 
weeks (Figure 4.6b). Motor performance was monitored by the elevated beam test 
and rotarod every other week between 6 to 12 weeks of age. The mice were weaned 
with three weeks of age.  
 
4.2.3 Unaltered physiological parameters in MCT fed Plp-tg mice 
Medium chain triglycerides were shown to facilitate ketone body production 
compared to long chain triglycerides, which are the main constituent of the classical 
ketogenic diet (Huttenlocher et al., 1971). Therefore, a MCT diet regime allows a 
higher intake of carbohydrates and proteins, facilitating digestion with a similar 
synthesis rate of ketone bodies in epileptic patients (Sills et al., 1986). To determine 
diet induced metabolic changes as a measure of liver ketogenesis, glucose and β-
hydroxybutyrate levels in blood samples were analyzed (Figure 4.7a). In contrast to 
patients with epilepsy (Huttenlocher et al., 1971), blood concentration of β-
hydroxybutyrate during MCT diet increased only slightly and blood glucose was not 
altered as expected (Eckel et al., 1992). Furthermore, evaluating motor performance 
on the elevated beam test revealed unaltered motor function in Plp-tg mice fed MCT 
diet (Figure 4.7b). Due to the small treatment benefit of MCT diet, the MCT treatment 






Figure 4.7I MCT diet revealed unaltered motor performance in Plp-tg mice. (a) Evaluation of 
glucose and β-hydroxybutyrate level in blood samples taken from the tail tip of non-transgenic 
wildtype, Plp-tg mice fed SD or MCT diet. One-way-ANOVA with Tukey’s multiple comparison 
test was performed (n=4-8). (b) Elevated beam test as a measure of motor performance was 
done with wildtype and Plp-tg mice fed SD or MCT diet (n=4-8). Results were unaltered and 
therefore assigned not significant (ns). 
 
4.2.4 Increase ketone body metabolism in Plp-tg mice fed KD 
Since classical KD provides 94% kcal as fats compared to 70% kcal in the MCT diet 
(Figure 4.6a), a stronger change in physiological parameters reflecting enhanced 
ketogenesis was expected. Hence, blood β-hydroxybutyrate, blood glucose (Figure 
4.8a) and body weight (Figure 4.8b) were monitored weekly. β-Hydroxybutyrate 
levels stayed persistently increased through the entire treatment period (Mean of 3-
12 weeks of age for Plp-tg 0.63±0.04mg/dL on SD compared to 5.76±0.18 on KD). 
A strong reduction in blood glucose was determined one week after treatment start, 
at three weeks of age. Interestingly, blood glucose normalized during the ten weeks’ 
treatment period (Plp-tg 3 weeks of age 139.5±15.89mg/dL SD compared to 
95.33±9.11 KD; 12 weeks of age 200.8±7.87mg/dL SD compared to 154.2±13.96 
KD). The increase in blood β-hydroxybutyrate as well as the decrease in blood 
glucose was expected (Mantis et al., 2014). Despite the expected observation that 
KD led to a strong reduction in the gain of body weight (Plp-tg 12 weeks of age 16±1g 
KD in comparison to 26±1 SD), mice appeared healthy and lively in accordance with 




unaltered serum pH (Figure 4.8c), which indicates that Plp-tg mice on KD did not 
suffer from ketoacidosis. Plp-tg mice fed KD revealed a persistent and reliable 
alteration of metabolism without any concerns about the safety and tolerability of KD. 
This provided the prerequisite for the analysis of a potential KD treatment benefit for 
Plp-tg mice.  
 
 
Figure 4.8I KD highly increased ketone body abundance in the blood of Plp-tg mice. (a) 
Blood glucose and β-hydroxybutyrate levels measured in non-transgenic wildtype and Plp-tg mice 
fed SD or KD. Two-way-ANOVA with Bonferroni’s post test revealed significant difference 
between Plp-tg mice fed SD or KD. (b) Body weight of Plp-tg animals fed KD compared to SD fed 
littermate controls. Quantification was performed by two-way-ANOVA with Bonferroni’s post test. 
(c) Serum pH at 12 weeks of age in wildtype and Plp-tg mice fed SD or KD. Differences were 
considered significant with a P-value of *, P<0.05; ****, P<0.0001. 
 
4.2.5 Plp-tg mice fed KD show reduced markers for microgliosis, but not 
astrogliosis 
Marked inflammatory responses are associated with disease expression in Plp-tg 
mice, including microgliosis and astrogliosis (Epplen et al., 2015; Prukop et al., 2014; 






Figure 4.9I Reduced microgliosis and unaltered astrogliosis in Plp-tg animals. (a) GFAP 
and MAC3 stainings in the CST of non-transgenic wildtype, Plp-tg mice on SD and KD. (b) 
Histological evaluation showing the number of activated microglia (MAC3) (n=4-6), and the GFAP 
positive area for reactive astrocytes in the CST of wildtype and Plp-tg mice (n=4-11). One-way-
ANOVA with Tukey’s multiple was performed. (c) Normalized quantitative RT-PCR on dissected 
lumbar spinal cord tissue determining the marker genes for activated microglia (Aif1) and reactive 
astrocytes (Gfap). One-way-ANOVA with Tukey’s multiple comparison test revealed differences 
for Plp-tg mice on SD compared to KD. (P-values of *, P<0.05; **, P<0.01; ***, P<0.001; ****, 
P<0.0001; ns = not-significant, scale bar, 20µm). 
 
To address, whether KD leads to reduced inflammation in Plp-tg mice, we evaluated 
astrogliosis with the use of a marker for reactive astrocytes, GFAP (glial fibrillary 




immunohistochemistry staining for MAC3 (macrophage-3 antigen) which stains 
activated, including phagocytic, microglia.  
Quantification of astrogliosis in Plp-tg mice fed SD revealed a strong GFAP positive 
signal in the cortical spinal tract (CST) (Figure 4.9a). Interestingly, Plp-tg mice fed 
KD showed unaltered astrogliosis, indicated by comparable GFAP positive area to 
SD littermates (Plp-tg mice: 9.5±0.91 GFAP+ area SD compared to 8.9±0.62 KD) 
(Figure 4.9b). However, an about 50% reduction of Gfap expression (Figure 4.9c) in 
whole lumbar spinal cord lysates including further grey matter parts suggests 
decreased astrogliosis.  
Histological quantification of microgliosis in the CST of Plp-tg mice revealed a 
significant increase in MAC3 positive cells in Plp-tg mice fed SD compared to 
wildtype controls (Figure 4.9a). Feeding KD strongly reduced microgliosis (Plp-tg 
mice: 15.2±0.79 MAC3+ cells SD compared to 11.7±0.75 KD in the CST) (Figure 
4.9b). The reduced microgliosis in KD fed Plp-tg mice was further supported by 50% 
decreased mRNA expression of the microgliosis marker Aif1 (allograft inflammatory 
factor 1) (Figure 4.9c). These data suggest that KD led to ameliorated gliosis in Plp-
tg mice. Furthermore, astrogliosis was shown to be highly persistent at the twelve 
weeks’ time-point, indicating that KD treatment did not influence the number of 
activated astrocytes. 
 
4.2.6 Increased oligodendrocyte numbers in KD fed Plp-tg mice 
Oligodendroglial differentiation is characterized by the expression of marker proteins. 
Immature oligodendrocytes, named oligodendrocyte precursor cells (OPC’s) 
synthesize NG2 (nerve-glia antigen 2 proteoglycan), whereas mature 
oligodendrocytes express CAII (carbonic anhydrase II). Olig2 (oligodendrocyte 
lineage transcription factor 2) is expressed by the complete oligodendroglial lineage.  
The demyelinating and dysmyelinating pathology of Plp-tg animal includes the early 
loss of oligodendrocytes (Readhead et al., 1994). This defect is supposedly 
paralleled by enhanced OPC differentiation in the attempt to maintain functionality. 
To test whether KD treatment of Plp-tg mice might influence the abundance of 
oligodendroglia, we performed histologically analyses with stainings detecting NG2, 
CAII and Olig2 in the CST of Plp-tg mice (Figure 4.10a). Quantification of NG2 




on SD and a further elevation when feeding the KD (WT: 5.6±0.43 NG2+ cells; Plp-
tg mice: 10.2±0.37 SD compared to 12.2±0.49 KD). The CAII staining showed highly 
reduced numbers of mature oligodendrocytes in Plp-tg mice on SD compared to 
wildtype mice.  
 
 
Figure 4.10I KD increased oligodendrocyte numbers in Plp-tg mice. (a) Stainings of NG2 
(oligodendrocyte progenitor cells), CAII (mature oligodendrocytes) and Olig2 (oligodedrocyte 
lineage) in the CST of wildtype, Plp-tg mice on SD and KD. Histological evaluation showing the 
number of OPCs (NG2; n=5-9), mature oligodendrocytes (CAII; n=4-9) and the whole 
oligodendrocyte lineage (Olig2; n=4-9). Three sections per animal were staining for quantification. 
One-way-ANOVA with Tukey’s multiple comparison test showed a significant difference between 
groups. (b) Quantitative RT-PCR on dissected lumbar spinal cord tissue determining the 
expression of Cspg4, Car2, Olig2 and, Plp1, Mbp and Mog normalized by Rplp0 (ribosomal 
protein P0). One-way-ANOVA with Tukey’s multiple comparison test was performed and 
differences were considered significant with a P-value of *, P<0.05; **, P<0.01; ****, P<0.0001; 




In contrast, Plp-tg animals fed KD revealed rescued numbers of mature 
oligodendrocytes in the CST (WT: 21.3±0.91 CAII+ cells; Plp-tg mice: 14.4±0.78 SD 
compared to 19.7±1.12 KD). 
The same tendency was monitored for Olig2 staining (WT: 15.0±0.63 Olig2+ cells; 
Plp-tg mice: 11.4±1.19 SD compared to 16.9±1.44 KD). Therefore, these data imply 
that feeding KD to Plp-tg mice supports OPC differentiation and oligodendrocyte 
stability. Quantification of the relative expression level of oligodendroglial (Olig2, 
Car2 for CAII and Cspg4 for NG2) and myelin related proteins (Plp1, Mbp, Mog) 
showed a significant increase in Olig2 expression in KD fed Plp-tg mice (Figure 
4.10b). This finding might reflect increase oligodendrocyte stability. The results of 
increased CAII staining and unaltered Car2 expression in Plp-tg mice fed KD might 
be explained by the analysis of different tissues, CST versus whole lumbar spinal 
cord lysates, respectively.  
 
4.2.7 Increased numbers of myelinated axons in the CST of KD fed Plp-tg 
mice 
Elevated numbers of OPCs and mature oligodendrocytes point to the hypothesis that 
also myelination might be increased in KD fed Plp-tg mice. Therefore, electron 
micrographs were evaluated for the number of myelinated axons and the g-ratio in 
the CST of Plp-tg animals. Ten pictures of single animals were analyzed in regard to 
the classification of myelinated or unmyelinated axons and the quantification of the 
g-ratio. Quantification revealed unaltered distribution of axon caliber in the CST of 
Plp-tg mice (Figure 4.11a). 
The g-ratio analysis, reflecting the ratio of fiber diameter divided by axon diameter, 
was unaltered in the cloud diagram between Plp-tg mice on SD and KD (Figure 
4.11b). The significant decrease in myelin thickness of Plp-tg mice compared to 
wildtype animals was not rescued by feeding KD shown by the measurement of the 
mean g-ratio. However, plotting the measured g-ratio as a relative frequency 
distribution with the g-ratio of 0.8 as a border, since it was shown to provide sufficient 
insulation capacity for proper conduction velocity (Waxman, 1980), myelinated axons 
below 0.8 showed increased abundance (g-ratio <0.8 in Plp-tg mice: 25.0±5.16% SD 
compared to 38.1±2.93 KD). Furthermore, a strong decrease in unmyelinated axons 




WT: 4.6±0.51% and Plp-tg mice: 33.4±0.92 SD compared to 23.4±3.08 KD) (Figure 
4.11c).  
In summary, Plp-tg mice fed KD showed elevated levels of oligodendrocytes as well 
as increased numbers of myelinated axons both within the CST. 
 
 
Figure 4.11I Feeding KD increases the number of myelinated axons in Plp-tg animals. (a) 
Relative frequency distribution of axon calibers in Plp-tg mice on SD and KD (n=7). Student’s t-
test revealed unaltered distribution. (b) G-ratio analysis of only myelinated axons of the CST from 
wildtype mice, and Plp-tg mice on SD and KD (n=7). One-way-ANOVA with Tukey’s multiple 
comparison test. (c) Relative frequency distribution of the g-ratio results from wildtype mice, Plp-
tg mice on SD and KD divided in<0.8, >0.8 and 1 for unmyelinated axons. Significance was tested 
with one-way-ANOVA with Tukey’s multiple comparison test. Differences were considered 






4.2.8 Feeding a ketogenic diet improved motor performance in Plp-tg mice 
Since the Plp-tg mice fed KD for ten weeks showed a reduced gain in body weight, 
the physical condition was analyzed every other week from six until twelve weeks of 
age by rotarod performances. Furthermore, to address the question, whether the 
amelioration of the hypomyelination benefits the affected motor pathology of Plp-tg 
mice, elevated beam tests were performed as described before (Saher et al., 2012).  
The rotarod can be used as a measure for motor coordination and alterations might 
reflect impaired physical condition. The used rotarod set-up consisted of a circular 
rod turning with increasing speed over time (max. 26 rpm in 150 sec). Quantifications 
were performed by measuring the accomplished max. speed per animal. Plp-tg mice 
fed SD showed decreased motor performance with increasing age (Figure 4.12a). In 
contrast, Plp-tg mice treated with KD showed comparable motor performance on the 
rotarod to wildtype animals (rotarod speed at 12 weeks WT: 23.9±1.09rpm and Plp-
tg mice: 15.5±1.30 SD compared to 21.7±0.99 KD). Therefore, the decreased body 
weight did not reflect impaired physiological conditions. 
The elevated beam test revealed increased numbers of slips for the Plp-tg mice on 
SD compared to wildtype mice (Figure 4.12b). Interestingly, the number of slips was 
reduced to wildtype levels in KD fed Plp-tg mice (beam test at 12 weeks WT: 
0.15±0.07 slips and Plp-tg mice: 1.29±0.23 SD compared to 0.15±0.8 KD). 
 
 
Figure 4.12I Feeding KD to Plp-tg mice improved motor performance. (a) Rotarod 
performance of wildtype and Plp-tg mice fed SD or KD chow evaluated at 6, 8, 10 and 12 weeks 
of age. Significance was tested using two-way ANOVA with Sidak’s post test. (b) Elevated beam 
test performance of wildtype animals and Plp-tg mice fed SD or KD evaluated at 6, 8, 10 and 12 
weeks of age. Two-way ANOVA with Sidak’s post test revealed significantly improved motor 
performance in Plp-tg mice fed KD compared to SD animals. Differences were considered 
significant with a P-value of *, P<0.05; ***, P<0.001; ****, P<0.0001. 
Both behavioral analyses showed amelioration of the affected motor phenotype of 





4.2.9 Increased ketone body uptake and consumption in Plp-tg mice treated 
with KD 
Since KD provided an overall benefit for Plp-tg mice by reduced inflammation, 
increased oligodendrocyte numbers, enhanced myelination and ameliorated motor 
performance, we wanted to investigate KD induced metabolic changes, which could 
favor the ameliorated pathology. Fatty acids that have been converted to ketone 
bodies in the liver are able to cross the BBB mediated by monocarboxylate 
transporters (MCT) and serve as alternate source for energy and anabolic 
metabolism. To elucidate whether the Plp-tg mice treated with KD show altered 
ketone body metabolism within the CNS (lumbar spinal cord tissue was used for 
comparison with previously tested parameters), the expression level of important 
enzymes involved in ketone body uptake and ketolysis, were analyzed. 
Quantification of qRT-PCR results revealed unaltered expression of both 
monocarboxylate transporters, MCT1 and MCT2 in Plp-tg mice fed SD and an 
elevation for Plp-tg mice fed KD. MCT1, which is expressed in glia cells and mainly 
endothelial cells, showed a twofold increase in expression, and MCT2, mainly 
expressed on neurons increased the expression level by about 50% (Figure 4.13a). 
These results suggest increased uptake of ketone bodies in glial cells and neurons 
of the CNS. The main enzymes involved in ketolysis are BDH1 (β-hydroxybutyrate 
dehydrogenase 1), OXCT1 (3-oxoacid CoA-transferase 1) and ACAT1 (acetyl-coA 
acetyltransferase 1) (see Introduction Figure 4.4). In Plp-tg mice fed KD, the 
expression level of Bdh1 as well as Acat1 were significantly increased compared to 
control littermates (Bdh1 Plp-tg mice: 0.62±0.02 rel. exp. SD compared to 0.83±0.05 
KD; Acat1 Plp-tg mice: 0.6±0.02 rel. exp. SD compared to 0.8±0.05 KD) (Figure 
4.13b). Oxct1, which expresses the rate limiting enzyme for ketolysis, shows 
increased protein abundance in the process of ketone body consumption, rather than 
increased expression levels (Schnyder et al., 2017). Accordingly, Oxct1 expression 
level in qRT-PCR analysis was unaltered compared to control littermates (Figure 
4.13b). Quantification of OXCT1 protein abundance on western blot revealed a 
significant increase in KD fed Plp-tg mice compared to SD suggesting enhanced 




Together, these data suggest not only elevated uptake of ketone bodies in the spinal 
cord, but also increased ketone body metabolism to build up acetyl-CoA. The 
metabolite acetyl-CoA can be used in various pathways e.g. to produce energy in 
form of ATP via the TCA cycle and oxidative phosphorylation or it can be used to 
build up fatty acids or cholesterol to increase myelination. 
 
 
Figure 4.13I Increased ketone body uptake and ketolysis in KD fed animals. (a) Quantitative 
RT-PCR on dissected lumbar spinal cord tissue determining the expression of markers for ketone 
body uptake Mct1 and Mct2. (b) Markers for ketolysis Bdh1, Oxct1 and Acat1 (c) Western Blot 
quantification of OXCT1 for wildtype mice (n=3), Plp-tg mice on SD (n=3) compared to KD (n=4). 
Equal protein load was confirmed with a comparable staining of actin. (d) Markers for fatty acid 
synthesis (Acc1, Fasn) and cholesterol synthesis (Hmgcs1, Hmgcr). Significance was tested 
using one-way-ANOVA with Tukey’s multiple comparison test. Results were normalized to 
untreated wildtype mice and significant was depicted only between Plp-tg groups. Differences 
were considered significant with a P-value of *, P<0.05; **, P<0.001; ****, P<0.0001. 
 
Due to the fact that increased oligodendrocyte numbers as well as elevated levels of 
myelinated axons in the CST were quantified, increased fatty acid and cholesterol 
synthesis were expected. The expression level of Acaca (acetyl-coA carboxylase 1, 




were analyzed. Additionally cholesterol synthesis with Hmgcs1 (3-hydroxy-3-
methylglutaryl-coA synthase 1), Hmgcr (3-hydroxy-3-methylglutaryl-CoA reductase), 
the rate-limiting step in cholesterol biosynthesis and Fdftf1 (farnesyl-diphosphate 
farnesyltransferase 1), also known as squalene synthase, which catalyzes the first 
dedicated step to cholesterol biosynthesis (Figure 4.13e) were quantified.  
 
Only a significant increase in Fdft1 expression was detected (Fdft1 Plp-tg mice: 
0.45±0.02 rel. exp. SD compared to 0.53±0.02. KD), which might indicate ongoing 
myelination. Together, evaluation of fatty acid and cholesterol synthesis revealed 
almost unaltered synthesis rates indicating that ketone bodies might be 
predominantly used to provide acetyl-CoA for the energy metabolism, but these 
needs to be further elucidated.  
 
4.2.10 Decreased accumulation of PLP in endo/lysosomal compartments 
Results from cultured Plp1-transgenic oligodendrocytes revealed that PLP 
overexpression causes the accumulation of PLP and cholesterol in the late 
endosome/ lysosome (Simons et al., 2002). Feeding of a cholesterol-rich diet was 
shown to prevent the oligodendrocyte from PLP accumulation (Saher et al., 2012). 
To address the question whether feeding a KD might decrease lysosomal PLP 
accumulation, co-staining of PLP1 and Lamp1, detecting the endosome/lysosome 
compartment, was performed. 
The co-staining revealed that in Plp-tg animals, PLP accumulates in the 
endosome/lysosome compartments of the CST. Notably, feeding KD to Plp-tg 
animals decreases PLP/Lamp1 positive co-staining (preliminary data, not quantified) 







Figure 4.14I Ketogenic diet reduces lysosomal PLP1 accumulation. (a) Plp1 (green) and 
Lamp1 (red) staining, for accumulated Plp1 in the late endosome/lysosome (Lamp1) in the 
corticospinal tract of wildtype, Plp-tg mice on SD and KD. Scale bar 20µm, selection 2µm. (b) 
Quantitative RT-PCR on dissected lumbar spinal cord tissue determining the expression of 
markers for lysosomal degradation and transport Man2b1, Hexa Npc1 and Npc2. Normalization 
was performed with Rplp0. Results were normalized to untreated wildtype mice and significant 
was depicted only between Plp-tg groups. One-way-ANOVA with Tukey’s multiple comparison 
test was performed. Differences were considered significant with a P-value of **, P<0.01. 
Numbers in the bar diagram reveal the P-values, if significance was not given. 
 
One of the main functions of lysosomes is the degradation of intracellular material 
mediated by acid hydrolases, such as alpha-mannosidase (Man2b1) for the 
breakdown of mannose bound to imported glycoproteins and hexosaminidase 
(Hexa) for the breakdown of GM2 ganglioside. The expression of alpha-
mannosidase and hexosaminidase showed a high increase in Plp-tg mice compared 
to wildtype animals. Moreover, expression was further elevated in KD fed animals 
compared to control littermates (Man2b1 Plp-tg mice 2.28±0.09 rel. exp. SD 
compared to 2.7±0.10 KD; Hexa Plp-tg mice: 3.25±0.25 rel. exp. SD compared to 
3.81±0.12 KD) (Figure 4.14b). 
Membrane remodeling and short-term storage of endocytosed cholesterol is 
performed by two lysosomal proteins, Niemann-Pick disease type C1 (NPC1) and 
type C2 (NPC2). NPC1 encodes for a large membrane protein and NPC2 for a small 
soluble protein. Upon axonal signaling (Trajkovic et al., 2006), these two proteins 




compartment. Evaluating the expression level of Npc1 and Npc2, a slight increase 
was detected in mice fed KD compared to control littermates (Npc1 Plp-tg mice: 
0.75±0.04 rel. exp. SD compared to 0.86±0.05 KD; Npc2 Plp-tg mice: 1.37±0.06 rel. 
exp. SD compared to 1.67±0.16 KD). The increase in gene expression might reflect 
a compensatory mechanism to exocytose accumulated cholesterol together with 
PLP for reintegration into the secretory pathway. Whether axonal signals contribute 
to the increased expression of NPC proteins needs further investigation.   
In summary, the results suggest decreased PLP abundance in the endo/lysosomal 
compartment, increased expression of degrading enzymes as well as elevated levels 
of lysosomal cholesterol transport proteins.  
 
4.2.11 Reduced ER stress in Plp-tg mice fed KD 
It is well known that PLP missense mutations cause high ER stress responses with 
the induction of the unfolded protein response (UPR) (Roboti et al., 2009; Southwood 
et al., 2002). Elevated myelination as well as decreased PLP accumulation in the 
endosome/lysosome compartment might indicate that also a reduced amount of PLP 
is retained within the ER leading to minor ER stress response. Therefore, we 
investigated whether PLP overexpression in the Plp-tg mice causes an ER stress 
response and whether KD might alter the ER stress response. Furthermore, 
degradation of overexpressed PLP was shown to be mainly performed through the 
action of the cytosolic proteasome (Karim et al., 2010). The ER export of unfolded or 
retained proteins for proteasomal degradation is mediated by a pathway called 
endoplasmic-reticulum-associated protein degradation (ERAD) (Anelli and Sitia, 
2008). Since elevated levels of the ER-stress transcription factors Atf6 and Xbp1 
were shown to increase the expression of ERAD transcription factors (Kaneko et al., 
2007), the expression level of Atf6 (Activating transcription factor 6), Xbp1 (Xbox 
binding protein 1) and additional marker were analyzed.  
Interestingly, expression analysis revealed a high increase especially in Atf6 as well 
as Xbp1 expression in Plp-tg mice on SD. This effect was significantly reduced in KD 
fed animals compared to control littermates (Atf6 Plp-tg mice 4.08±0.37 rel. exp. SD 
compared to 2.51±0.15 KD; Xbp1 Plp-tg mice 4.58±0.18 rel. exp. SD compared to 
3.04±0.35 KD) (Figure 4.15a). Additionally, western blot analysis revealed increased 




the increase was rescued to wildtype levels in KD fed animals (ATF6 Plp-tg mice 
3.4±0.66 rel. abundance. SD compared to 0.74±0.08 KD) (Figure 4.15b). 
 
 
Figure 4.15I KD decreased ER stress response markers in Plp-tg mice. (a) Quantitative RT-
PCR on dissected lumbar spinal cord tissue determining the expression of markers for ER stress 
response, Atf6, Atf4, Xbp1, Bip and Chop normalized by Rplp0. Results were normalized, 
indicating the relative expression compared to untreated wildtype mice. (b) Western blot analysis 
of full length ATF6 with β-actin used for normalization (one representative wildtype) One-way-
ANOVA with Tukey’s multiple comparison test was performed and differences were considered 
significant with a P-value of *, P<0.05; **, P<0.01; P<0.01; ***, P<0.001; ****, P<0.0001. 
 
In summary, these set of experiments revealed an increased ER stress response in 
untreated Plp1-overexpressing mice. This effect was diminished by KD treatment of 
Plp-tg mice.  
 
4.2.12 Increased mitochondria size in Plp-tg mice can be rescued by KD 
treatment.  
Myelin is essential for proper axonal conduction velocity by providing electrical 
insulation and the loss of insulation is hypothesized to cause higher energy demands 
for thinly or unmyelinated axons. Furthermore, unmyelinated axons have a five-fold 
increased energy demand to preserve wiring capacity in comparison to myelinated 
axons with the same diameter (Neishabouri and Faisal, 2011). In a severe model of 
PMD it was shown that Plp-tg mice (Plp-tg66/66 with 7 copies of the transgene 




spinal cord accompanied by mitochondria dysfunction and decreased ATP levels 
(Ruiz et al., 2017). To address the question whether our Plp-tg mice (Plp-tg72/72) show 
also increased mitochondria size in spinal cord axons, mitochondria size on electron 
micrographs of the CST of Plp-tg mice at the age of twelve weeks was analyzed.  
 
 
Figure 4.16I Ketogenic diet rescues mitochondria enlargement in Plp-tg mice. (a) 
Quantification of mitochondria size in the CST of wildtype mice, and Plp-tg animals on SD or KD 
(n=4-7). 100 mitochondria per animal were counted in approximately 80 axons. Differences 
between groups were evaluated with the one-way-ANOVA with Tukey’s multiple comparison test. 
(b) Mitochondria in the CST of Plp-tg mice on SD and KD. The unmyelinated axon is outlined in 
blue and the mitochondria colored in red. (c) Mitochondria size in µm2 divided in myelinated and 
unmyelinated axons for Plp-tg mice treated with SD or KD Scale bar 0.5µm. Differences were 
considered significant with a P-value of *, P<0.05; ***, P<0.001; ns = not-significant 
 
Interestingly, elevated numbers of mitochondria with increased size were found in 
Plp-tg mice fed SD compared to wildtype mice (Figure 4.16a/b). Surprisingly, 
mitochondria size was rescued to almost wildtype level by providing KD to the 




compared to 0.10±0.01 KD). Notably, the increased mitochondria size in SD fed Plp-
tg was limited to unmyelinated axons, suggesting altered mitochondrial function in 
unmyelinated axons of Plp-tg mice fed SD. In contrast, mitochondria of unmyelinated 
axons in Plp-tg mice fed KD showed unaltered size (mitochondria size of 
unmyelinated axons for Plp-tg mice 0.17±0.02µm2 SD compared to 0.11±0.01 KD) 
(Figure 4.16c).  
These data might suggest axonal mitochondria dysfunction especially in 
unmyelinated axons of our Plp-tg. Interestingly, feeding the KD to Plp-tg animals 
might provide a treatment strategy to address impaired mitochondrial function.  
 
4.2.13 Ameliorated axonal pathology in Plp-tg mice fed KD 
Data of the demyelination state and mitochondria size point to the assumption that 
especially unmyelinated axons of Plp-tg animals suffer from impaired mitochondrial 
metabolism, which could affect axonal health. As readout for axonal pathology, APP 
(amyloid precursor protein) staining was performed and axonal spheroids in the CST 
of Plp-tg mice were counted. The quantification exhibit highly increased numbers of 
APP positive spheroids within the CST of Plp-tg mice on SD compared to wildtype 
controls. These results suggest axonal impairments of untreated Plp-tg animals. 
Interestingly, Plp-tg mice fed KD showed a dramatic reduction of APP positive 
spheroids compared to control littermates on SD indicating increased axonal health 
in KD fed animals (WT: 3.6±1.01 APP+ spheroids; Plp-tg mice: 62.4±7.37 SD 
compared to 25.6±1.9 KD) (Figure 4.17).  
Taken together, these data showed enhanced axonal pathology in untreated Plp-tg 






Figure 4.17I Decreased number of APP positive axonal spheroids in KD fed animals. APP 
staining in the CST of non-transgenic wildtype, Plp-tg mice on SD and KD. Quantification of the 
number of APP positive axonal spheroids (n=6-8). Three sections per animal were staining for 
quantification. One-way-ANOVA with Tukey’s multiple comparison test were performed with 










4.3.1 Phenotypical changes of Plp-tg mice 
The first challenge of the experimental work was the unexpected phenotypical 
change of Plp-tg mice. Overall, the current Plp-tg mice showed reduced disease 
expression compared to the same mouse colony in 2012, including ameliorated 
hypomyelination pathology accompanied by less severe inflammation and improved 
motor performance. We investigated whether loss of transgene copy might explain 
the phenotypic alterations, but overexpression of Plp1 mRNA in brain lysates was 
still detectable to the same extend as shown previously (Prukop et al., 2014). Another 
possibility might be that Plp-tg mice experienced an unspecific genetic drift and that 
the infection of mites and helminths provoked a highly selective environment, 
spreading the genetic alteration throughout the mouse colony. Many inbred 
laboratory mouse strains are prone to genetic alterations due to heterozygote 
selection, mutations or contamination by uncontrolled breeding between different 
strains (Casellas, 2011). In fact, Plp-tg mice suffer from toxic accumulation of PLP 
protein, one possibility to explain the weaker phenotype might be by diverse 
alteration of the PLP degradation machinery (e.g. increased expression of ERAD 
components). Increased PLP degradation would lead to stress release in 
oligodendrocytes which might cause enhanced oligodendrocyte survival with 
secondarily reduced inflammation and reduced hypomyelination. Another example 
might be that an unspecific genetic drift affected the translation of Plp mRNA into 
PLP protein, which might lead to decreased levels of PLP protein and therefore 
release of cell stress. However, the detection of genetic alterations is only possible 
by the performance of a full genome scan of the mouse line, at best in comparison 
with phenotypically unaffected control mice of previous cohorts. Even after 
localization of the genetic alteration, the reestablishment of the former genotype 
remains challenging. Since this study focused on a novel therapeutic approach by 
feeding a lipid-based KD, we decided to perform our new experimental design with 






4.3.2 Mitochondrial dysfunction contributes to axonal loss 
Our study provides insight in structural alterations of axonal mitochondria in the CST 
of untreated Plp-tg mice, which is in accordance with another study of Plp 
overexpressing mice (Plp-tg66/66; (Ruiz et al., 2017). Plp-tg72/72 mice at the age of 
twelve weeks exhibit highly increased mitochondrial size in unmyelinated axons of 
the CST. Our results are supported by the finding that Plp-tg72/72 showed increased 
mitochondrial density in the optic nerve especially at advanced demyelination state 
with four month (Hogan et al., 2009). Furthermore, Plp-tg overexpressing mice (Plp-
tg66/66) showed decreased ATP levels to about 50% in whole brain tissue (Hüttemann 
et al., 2009). In addition calculation using a stochastic, biophysical model revealed a 
five-fold increased energy demand to preserve wiring capacity of unmyelinated 
axons in comparison to myelinated axons with the same diameter (Neishabouri and 
Faisal, 2011). Therefore, the increased axonal mitochondria size and elevated 
mitochondria density might be a compensatory mechanism of axons to adapt to the 
higher energy needs upon severe demyelination. 
Further, overexpressed PLP seems to be highly associated to the inner mitochondrial 
membrane accompanied with reduced mitochondrial membrane potential and 
increased mitochondrial biogenesis in brains of five weeks old mice (Hüttemann et 
al., 2009). In accordance, cysteine motifs of PLP protein were demonstrated to be 
recognized by the Mia40/Erv1 pathway for mitochondrial import (Appikatla et al., 
2014). Mitochondrial PLP association was accompanied by decreased pH levels in 
media. Furthermore, DRG neurons co-cultured with Plp-overexpressing HEK cells 
showed an acidification of cultivation media leading to reduced neuronal viability 
(Boucher et al., 2002). These results suggest an effect of elevated PLP levels on 
neuronal health in addition to a direct effect of PLP overexpression on mitochondrial 
function. Therefore, PLP accumulation in oligodendroglial mitochondria might cause 
mitochondrial dysfunction with the disruption of axonal energy supply ultimately 
leading to neuronal death (Hüttemann et al., 2009).  
These results might suggest a mechanism by which increased axonal energy 
demands, due to accumulated PLP and demyelination, could lead to an increase in 
mitochondria density or the elevation of mitochondrial function accompanied by an 
increase in size. Upon disease progression with highly severe demyelination of 
axons, the theoretical mitochondrial adaptation to axonal energy requirement might 




resulting in axonal death. However, direct evidence for an in vivo mechanism is 
lacking. Nevertheless, these observations in combination with our data support a 
possible therapeutic target by providing a metabolic alternative to axons to cover for 
increased energy demands. 
 
4.3.3 KD therapy ameliorated disease severity in Plp-tg mice 
The present study further proposes a novel therapeutic approach for the 
leukodystrophy Pelizaeus-Merzbacher disease (PMD) by feeding a lipid-based KD. 
Previously, KD treatment was shown to provide anti-inflammatory properties, 
increase oxidative phosphorylation and reduce oxidative stress in mitochondria 
(Abou-Sleiman et al., 2006; Bough and Rho, 2007; Yang and Cheng, 2010). 
Moreover, KD treatment might induce a metabolic switch that could enhance 
myelination due to fact that ketone bodies are predominantly used for the synthesis 
of fatty acids and especially cholesterol (Webber and Edmond, 1977). Therefore, KD 
provided the perfect requirements for the treatment of neurodegenerative diseases 
associated with hypomyelination and mitochondrial malfunctions such as PMD. 
Hence, Plp-tg mice were used to investigate whether increased cerebral ketone body 
metabolism might provide advantages to ameliorate PMD disease severity. 
The mammalian brain requires high amounts of energy to sustain essential functions, 
like neuronal activity and recycling of neurotransmitters (Bélanger et al., 2011). 
Despite the use of glucose as primary energy source, brain cells metabolize other 
substrates such as fatty acids or ketone bodies during glucose deprivation or 
increased energy demands (Ebert et al., 2003; Morris, 2005). According to our 
hypothesis, ketone bodies as alternative metabolites might be able to increase local 
cholesterol synthesis (e.g in astrocytes) to support oligodendrocytes from Plp 
accumulation, by restoring the ratio of cholesterol and Plp as it was shown before 
(Saher et al., 2012). Furthermore, we speculate that KD might enhance local energy 
production (e.g in astrocytes or neurons) by a glycolysis independent pathway to 





4.3.3.1 Reduced hypomyelination by KD treatment 
The application of KD diet to Plp-tg mice ameliorated disease severity with decreased 
hypomyelination. The increase in myelination might be due to enhanced OPC 
proliferation and increased stability of mature oligodendrocytes. In vivo tracing of 
labeled β-hydroxybutyrate and acetoacetate revealed that ketone bodies are 
predominantly used for the synthesis of fatty acids and especially cholesterol 
(Webber and Edmond, 1977). Moreover, it was shown that dietary cholesterol 
application in our mouse line restored oligodendrocyte numbers and increased 
myelination (Saher et al., 2012). Furthermore, cholesterol supplementation in the 
cuprizone model, a model for de- and remyelination, revealed increased OPC 
proliferation and oligodendrocyte differentiation (Berghoff et al., 2017b). Our data 
showed an increase in mRNA abundance of squalene synthase (Fdftf1), which 
catalyzes the first dedicated step to cholesterol biosynthesis. This increase possibly 
reflects elevated myelination, but it might also suggest that feeding a KD increases 
the synthesis of cholesterol, thereby supporting myelination. Considering that ketone 
bodies in young rodents are used to synthesize lipids and especially cholesterol for 
the integration in the myelin sheath (Koper et al., 1981) might support the assumption 
that KD enhances cholesterol synthesis, thereby increasing myelination. 
Furthermore, ketone bodies might facilitate lipid synthesis, since aceto-acetyl-CoA, 
which is produced during ketolysis can be directly integrated in fatty acid synthesis. 
In contrast glycolytic derived acetyl-CoA must first be converted to aceto-acetyl-CoA 
(Morris, 2005). Moreover, KD itself contains small amounts of cholesterol (0.09%), 
which could directly enter the CNS, since our Plp-tg mice suffer from impaired BBB 
function (Saher et al., 2012; this study).  
A highly speculative explanation might be that during PMD disease state, astrocytes, 
which are highly activated in our Plp-tg mice, might support axons with lactate to 
cover increased axonal energy requirements due to severe hypomyelination. 
Furthermore, PLP-laden oligodendrocytes might try to support axons as well. When 
PLP accumulation in oligodendrocytes would reach a certain threshold, myelination 
is impaired finally causing oligodendrocyte cell death. We showed that KD treatment 
of Plp-tg mice significantly increased mRNA expression of Mct1 and Mct2. Since 
endothelial cells and astrocytes express Mct1 (Zhang et al., 2014), these results 
might suggest enhanced ketone body import. Increased levels of intracellular ketone 




cholesterol support for oligodendrocytes. This would restore the ratio of cholesterol 
and PLP in accordance with our previous study (Saher et al., 2012), leading to 
increased myelination. This hypothesis might be supported by our finding that Plp-tg 
mice treated with KD revealed enhanced stability of mature oligodendrocytes.  
In contrast, HMG-CoA reductase, the rate limiting enzyme of cholesterol synthesis, 
showed unaltered mRNA expression in Plp-tg mice fed KD compared SD. Since 
evidence of a direct function of ketone bodies on astrocytic cholesterol synthesis are 
lacking, further experiments need to be performed to support this hypothesis. The 
next step could be to analyze cholesterol synthesis in vitro in a mutant mixed glia 
culture with and w/o the treatment of ketone bodies. Another possibility might be to 
extract glia cells from spinal cord tissue e.g by magnetic cell isolation to analyze the 
cell specific cholesterol synthesis related expression profile. Until then, we need to 
consider that KD treatment might ameliorate PMD disease pathology by another 
mechanism (see chapter 4.3.3.3). 
 
4.3.3.2 KD treatment reduced ER stress  
Overexpressed PLP has been shown to accumulate in the ER as well as in the 
endosome/lysosome compartment (Saher et al., 2012; Simons et al., 2002; 
Southwood et al., 2007). Increased ER stress in the PMD mouse model is highly 
associated with Plp missense mutation and rather modest changes were reported 
for mice with extra copies of the native Plp1 gene (Cerghet et al., 2002; Southwood 
et al., 2007). This study provides evidence of an enhanced ER stress response in 
the mild Plp-tg72/72 overexpressing mice with an increase in Xbp1 and Atf6 
transcription and ATF6 abundance. The transcription factors Atf6 and Xbp1 were 
shown to increase the expression of ERAD transcription factors (Hrd1 and Sel1) 
(Kaneko et al., 2007) and the induced cytosolic proteasome degradation machinery 
was proven to be the main pathway for degradation of overexpressed Plp (Karim et 
al., 2010). Our data revealed that by feeding a KD, Plp accumulation is decreased in 
the endosome/lysosome compartment. Furthermore, Plp overexpression associated 
ER stress is highly attenuated shown by decreased mRNA expression of Atf6 and 
Xbp1 reduced ATF6 protein level. The current study suggests that the amelioration 
of intracellular PLP accumulation might be a secondary effect due to the increased 




imported and metabolized by neighboring cells (e.g. astrocytes) to synthesize 
cholesterol for the support of highly impaired oligodendrocytes. This might restore 
the ratio of PLP and cholesterol and enhance myelination as it was shown before 
(Saher et al., 2012). Conclusively, reduction in ER stress response factors ATF6 and 
XBP1 might reflect the decreased PLP retention within the ER. This might be 
supported by the indicated amelioration of PLP accumulation in the 
endosome/lysosome. 
 
4.3.3.3 KD might provide metabolic support for neurons 
As mentioned above, mitochondrial dysfunction contributed to the severe axonal loss 
in Plp-tg mice. The current study demonstrates a treatment approach in which we 
supplied Plp-tg mice with alternative metabolites in form of ketone bodies. This study 
provides evidence that unmyelinated axons in the CST of Plp-tg mice suffer from 
mitochondrial alterations, which can be rescued by the treatment with KD. Moreover, 
overall axonal pathology (myelinated and unmyelinated axons) was reduced 
indicated by highly decreased axonal spheroids in the CST of Plp-tg mice after KD 
treatment. These data might also suggest that the KD especially supports 
unmyelinated axons with additional energy sources to compensate for local energy 
demands, which favors axonal health. Together these results raised the question 
whether neurons themselves are able to take up ketone bodies for local energy 
production or if other cell types provide energetic support via metabolic coupling.  
The major glucose transporter GLUT1 and the main ketone body transporter MCT1 
are highly expressed in astrocytes (Zhang et al., 2014). Astrocytic end-feet are 
involved in the maintenance of the BBB (Abbott et al., 2006). Therefore, they have 
direct access to glucose and ketone bodies transported via the blood stream. 
Interestingly, astrogliosis in the CST of Plp-tg mice was persistently increased 
comparing applications of SD and KD. This finding might possibly suggest astrocytic 






Figure 4.18I Working model of KD treatment to support axonal energy requirements. (a) In 
untreated Plp-tg mice on standard diet (SD), Plp accumulation in oligodendrocytes (OL) leads to 
OL cells death. Due to decreased numbers of OL, myelination and the axonal support by OL 
might be highly impaired. Consequently, upon disease progression most axons become severely 
demyelinated. Peripheral glucose (glu) can be imported by astrocytes (AC) via the Glut1 
transporter to perform glycolysis. Lactate is generated, which can be provided via metabolic 
coupling to unmyelinated axons. Axons can import lactate via Mct2 transporters to enhance local 
energy production. If axons suffer from energy deficiency, axonal conduction velocity is disrupted 
leading finally to axonal death. (b) Feeding a ketogenic diet (KD) might support axonal energy 
requirements in two distinct manners (1) ketone bodies (KB) can be transported via Mct1 into 
astrocytes. Astrocytes might metabolize KB for local energy demands and might use glycolysis 
derived lactate to provide it to axons. This mechanism would enhance axonal lactate supply by 
astrocytes. (2) KB might be directly imported into axons via Mct2 to be metabolized and used for 
local ATP production.  
 
In our model, we hypothesize that in untreated Plp-tg mice, astrocytes might provide 
energy depleted axons with lactate to preserve conduction (astrocyte-neuron lactate 
shuttle; Pellerin and Magistretti, 1994) (Figure 4.18a). Furthermore, also 




2012). In this study we show that upon disease progression in Plp-tg mice, 
oligodendrocytes suffer from accumulated PLP, which leads to increased 
oligodendrocyte cell death. Neurons might lose the speculated energetic support of 
oligodendrocytes. Further, postulated astrocytic support of neurons might become 
highly important (Pellerin and Magistretti, 1994). Demyelination in the CST of Plp-tg 
mice would lead to increased axonal energy demands, which might not be covered 
by astrocytic lactate support. Additionally to glucose metabolism, ketolysis by 
astrocytes might be beneficial to sustain the metabolic support of neurons (Figure 
4.18b (1)). In summary, we speculate that astrocytic ketolysis might provide 
neuroprotective properties by preserving neuronal function in a CNS disease state. 
However, we did not show that astrocytes increase the import of ketone bodies and 
use them to provide support to axons. Therefore, another possibility might be that 
neurons import ketone bodies to cover for their local energy demands. Neurons 
highly express the ketone body transporter Mct2 (Zhang et al., 2014). 
 
In our study we demonstrate that Mct2 mRNA expression was upregulated upon KD 
treatment, suggesting increased neuronal ketone body uptake. In rat hippocampal 
sliced cultures, neuronal acetyl-CoA metabolism is preferentially performed by β-
hydroyxbutyrate oxidation compared to glycolytic substrates (Valente-Silva et al., 
2015). Hence, we hypothesize that neurons are able to metabolize ketone bodies to 
cover their local energy demands (Figure 4.18b (2)). In neurons, ketone bodies can 
be converted to acetyl-CoA through a lactate independent metabolic pathway and 
directly integrated in the TCA cycle for local energy production.  
Taken together, our data demonstrates a novel therapeutic approach for the 
leukodystrophy PMD by the treatment with KD. This study highlights the benefit of 
KD on (1) the preservation of a stable oligodendrocyte pool for proper myelination 
and (2) the possible metabolic support of axonal energy requirements. These 
advantages favor reduced Plp accumulation, decreased ER stress and improved 
motor performance in Plp-overexpressing mice. Especially the ability of ketone 
bodies to enter the CNS might provide the major advantage for PMD patient, since it 
is still uncertain whether they exhibit BBB impairments.  
As a future perspective, KD treatment of PMD patients might improve their livelihood 
and ameliorate disease pathology as it was shown for our Plp-tg mice. Furthermore, 
clinical trials with KD have been approved for diverse neurological disease, which 




5 BBB manipulation with short-term isoflurane treatment enhances the 
delivery of cisplatin chemotherapy for glioblastoma treatment in mice 
5.1 Introduction 
5.1.1 Blood-brain-barrier 
5.1.1.1 BBB components 
The blood-brain barrier (BBB) regulates the flux of metabolites between the 
circulatory blood system and central nervous system. Furthermore, BBB protects the 
CNS from neurotoxic substances and pathogens. The blood system supplies the 
brain with oxygen and nutrients and eliminates carbon dioxide throughout the body. 
In return, the CNS releases signaling molecules such as hormones (Blood et al., 
2015). The cerebral spinal fluid (CSF) of the CNS has a unique composition, which 
allows execution of neuronal function. Disruption of CNS homeostasis (e.g. through 
diverse neurological diseases that affect BBB permeability) results in dysregulation 
of signaling pathways, uncontrolled immune responses, inflammation and finally 
failure of neuronal transmission. 
Endothelial cells (EC) form a thin layer endothelial tube enabling blood flow. In the 
CNS ECs are tightly connected to each other via specialized junctions, called tight 
junctions (Brightman, 1969; Reese and Karnovsky, 1967) (Figure 5.1). Brain ECs 
have unique physiological properties compared to other epithelial cells of the body 
to sustain the maintenance of barrier function. For instance, brain ECs revealed to 
have increased mitochondrial density (Oldendorf et al., 1977), which might reflect 
increased energy requirements due to the maintenance of transport function or 
preservations of tight junction structures. Moreover, decreased expression of 
leukocyte adhesion molecules in ECs is thought to restrict invasion of immune cells 
(Blood et al., 2015; Daneman et al., 2010a). 
In addition to ECs, pericytes and astrocytes play an important role in the development 
and maintenance of barrier function forming the Neurovascular Unit (NVU). Pericytes 
are in close contact to endothelial cells on the ablumenal surface, embedded in the 




derived growth factor β (PDGF-β) for pericyte recruitment and alteration of pericyte 
numbers can cause BBB dysfunction (Blanchette and Daneman, 2015). 
 
 
Figure 5.1I Components of the BBB. Endothelial cells form the linings of the blood vessels. 
Pericytes attached to the endothelial cell layer are embedded in the basal lamina. Astrocytic end-
feet ensheath almost the complete endothelial tube. Tight junction proteins, including occludin, 
claudin-5 and JAMs built the connection between adjacent endothelial cells. Scaffold proteins 
such as ZO-1 provide the intracellular connection of the tight junctions to the actin cytoskeleton. 
 
In recent years many functions of pericytes were unraveled such as the regulation of 
the capillary diameter (Peppiatt et al., 2006) or the control of cerebral blood flow (Hall 
et al., 2014). Furthermore, pericytes function in angiogenesis, wound healing and 
provide a regulatory role in the infiltration of immune cells (Daneman and Prat, 2015). 
During embryogenesis pericytes are indispensable for BBB formation, even before 
astrocytic end-feet attachment (Daneman et al., 2010b). Pericytes are critically 
involved in BBB maintenance indicated by severely enhanced BBB permeability for 
small and large molecular weight tracers in pericyte deficient mice (Armulik et al., 
2010). Upon pericyte deficiency astrocyte end-feet revealed abnormal polarization, 
indicated by altered abundance and localization of the water channel protein, 




regulating endothelial gene expression e.g. for the transferrin receptor (CD71), which 
functions in iron uptake 
The covering of endothelial cells and pericytes by the basal lamina membrane is of 
great importance, since it serves as an additional barrier for substances to enter the 
CNS. The basal lamina is composed of extracellular matrix proteins such as collagen, 
laminin, heparin sulfate proteoglycan and fibronectin, which are secreted by 
endothelial cells, pericytes and astrocytes (Keaney and Campbell, 2015). 
Furthermore, astrocytic derived laminin was shown to support pericyte differentiation 
by binding to integrin α2 receptor (Yao et al., 2014). Moreover, astrocytic derived 
laminin deficiency leads to decreased aquaporin 4 abundance and a reduced level 
of tight junction proteins, occludin and claudin-5.  
Astrocytes belong to the components of the NVU and play an important role in 
maintaining BBB function (Blanchette and Daneman, 2015). The extended astrocytic 
end-feet ensheath almost the complete endothelial tube (Abbott et al., 2006). These 
astrocytic borders, referred to as the glia limitans, provide functional barrier 
properties e.g. by restriction of immune cell infiltration (Sofroniew, 2015). 
Furthermore, in in vitro BBB models, ECs co-cultured with astrocytes provide 
enhanced transendothelial resistance, highlighting the importance of astrocytic 
function (Abbott and Friedman, 2012). In addition, astrocytes interact with pericytes 
and even neurons to adjust cerebral blood flow highlighting the interplay at the NVU 
(Attwell et al., 2010). 
Taken together, each component of the neurovascular unit possesses a distinct 
function and the complex crosstalk among them provides the basis for the strict 
regulation of BBB function.  
 
5.1.1.2 Tight and adherens junction proteins at the BBB 
The tight connection between adjacent endothelial cells is achieved through the 
action of tight and adherens junction proteins. Their main function is to prohibit 
paracellular passage ions (Bazzoni and Dejana, 2004). In general, tight junctions are 
divided in claudins, occludins, and junctional adhesion molecules.  
Claudins are tetraspan proteins at the BBB of the CNS that include four different 
isoforms, claudin-1,-3,-5 and -12 (Morita et al., 1999). All four isoforms are expressed 




tight junction protein (Jia et al., 2014). Mice lacking claudin-5 develop increased 
permeability of the BBB, but the passage was limited only to small molecules (Nitta 
et al., 2003). Claudin-5 function involves the restriction of ion permeability and the C-
terminus of claudin-5 provided the connection to cytoskeleton adapter proteins such 
as ZO proteins (Jia et al., 2014).  
Occludin with four transmembrane domains was shown to be important for barrier 
resistance. Transfection of a MDCK cell line (Madin-Darby canine kidney) with 
COOH-terminally truncated occludin revealed increased paracellular flux of 
especially small tracers (Balda et al., 1996). Overall tight junction appearance was 
reported to be normal. Since new analytic methods to investigate tight junction 
appearance (e.g. high-resolution microscopy) have been invented in the last 
decades, this statement needs to be reviewed. Deletion of occludin N-terminus led 
to a strong failure of tight junction assembly, with low transendothelial electrical 
resistance and diffusion of tracers (Bamforth et al., 1999). Mice lacking functional 
full-length occludin exhibit a mild BBB phenotype with high electrical resistance and 
only minor increases in calcium flux (Saitou et al., 2000). Tracer entries as well as 
other factors, which might contribute to tight junction formation in the absence of 
occludin, were not evaluated. Furthermore, occludin deficient mice developed 
several other defects like growth retardation, inflammation and altered bone structure 
pointing to other functions of occludin in addition to tight junction formation of the 
BBB. Occludin was shown to be highly prone to phosphorylation (Sakakibara et al., 
1997). Moreover, in MDCK I cells only highly phosphorylated occludin localized to 
tight junctions, whereas non- or less phosphorylated occludin was found at the 
basolateral membrane and in cytoplasmic vesicles. All together, these studies 
provided evidence that occludin contributes to tight junction stability and regulates 
paracellular BBB permeability.  
Junctional adhesion molecules (JAMs) are located between endothelial cells 
adjacent to occludin and claudins. JAMs contain two immunoglobulin-like domains 
and one transmembrane domain (Garrido-Urbani et al., 2014). Furthermore, the C-
terminal JAM domain protrudes into the cytosol and contains a protein binding 
domain (PDZ domain) for interaction with scaffold proteins such as ZO-1 (Stamatovic 
et al., 2012). JAMs were shown to regulate monocyte transmigration of the BBB 
(Martìn-Padura et al., 1998).  
Furthermore, tricellulin a novel tight junction protein with four transmembrane 




et al., 2005). Knockdown of tricellulin in cultured epithelial cells revealed altered 
distribution of claudin-3 and occludin pointing to tricellulin function in tight junction 
stability.  
Supporting the stability of endothelial connection in the intercellular cleft, the tight 
junction proteins are linked to the cytoskeleton by adaptor molecules like ZO-1 (zona 
occludens), ZO-2 or cingulin (Dejana, 2004). ZO proteins are junctional adaptor 
proteins that were shown to interact with the actin cytoskeleton as well as adherens 
and tight junction proteins. Knockdown of ZO-1 and ZO-2 in mouse cultured epithelial 
cells disrupted tight junction assembly (Umeda et al., 2006).  
Adherens junctions are involved in several functions such as regulation of cell-cell 
adhesion, connections with the cytoskeleton as well as intracellular signaling 
(Hartsock and Nelson, 2008). Furthermore, adherens junctions are supposed to be 
important to provide EC contact prior to tight junction assembly. In fact, adherens 
junction proteins strengthen EC contacts via connections to the cytoskeleton through 
the action of catenins (Dejana, 2004). For example VE-cadherin, the main EC 
adherens junction glycoprotein interacts with ZO-1 for actin cytoskeleton anchoring 
(Dejana et al., 2008). Moreover, VE-cadherin is supposed to play a role in 
maintaining barrier function through a process involving signaling of endothelial cell 
migration and angiogenesis (Tornavaca et al., 2015). N-cadherin functions in the 
interaction of ECs with pericytes, which additionally increased the tightness of the 
BBB (Gerhardt, 1999). PECAM1 (platelet EC adhesion molecules), a cellular 
adhesion and signaling receptor was shown to be involved in endothelial cell 
migration and leukocyte emigration (Woodfin et al., 2007). 
 
5.1.1.3 Transport across the BBB 
Due to the complex structure of tight and adherens junctions at the intercellular cleft 
of the ECs, paracellular transport is highly restricted (Figure 5.2a; Abbott et al., 2006). 
However, transcellular diffusion of some small lipophilic components (e.g. nicotine or 
alcohol) is possible (Figure 5.2b). Transport across the BBB mainly requires specific 
proteins or vesicle-mediated transcytosis (Abbott et al., 2006). Transport proteins 
such as nutrient transporters are very important for the metabolic supply of the CNS 
(Figure 5.2c). Nutrient transporters for primary metabolites of the CNS belong to the 




GLUT1 (Slc2a1) as the most abundant one. (Yudilevich and De Rose, 1971; 
Zlokovic, 2008). Monocarboxylate transporters (MCT) comprise a family of 14 
isoforms (Halestrap, 2013). MCT1 (Slc16A1), as the most abundant one, is 
expressed in all brain cells with the highest expression found in endothelial cells 
(Zhang et al., 2014). MCT1, MCT2 and MCT4 (Slc16A3) function in the transport of 
lactate and ketone bodies (acetoacetate and β-hydroxybutyrate). Furthermore, 
MCT1 and MCT2 are able to transport pyruvate (Halestrap, 2013). Efflux transporters 
in contrast to import transporters (e.g. SLCs) require energy in form of ATP for 
transport. The efflux transporter P-glycoprotein is largely responsible for the 
excretion of xenobiotics or undesired side products. (Figure 5.2c)(Barar et al., 2016).  
 
 
Figure 5.2I Transport routes across the BBB. (a) Paracellular transport is highly restricted for 
only very small aqueous molecules (e.g. hydrogen). (b) Transcellular passage through ECs can 
be performed by lipid-soluble agents. (c) Either influx or efflux of proteins is facilitated via transport 
proteins. Transcytosis can be divided in (d) receptor-mediated, by binding of a peptide to a 
receptor at the luminal membrane of the EC or (e) adsorptive, by the direct binding to the plasma 
membrane followed by vesicle invagination. (taken from Abbott et al., 2006) 
 
Furthermore, ECs contain vesicular transport systems, which include the function of 
either caveolae or clathrin-coated vesicles (Hervé et al., 2008). The vesicular 
transport of peptides with endocytic carriers is divided in receptor-mediated 
transcytosis and adsorptive transcytosis (Abbott et al., 2006). The receptor-mediated 




membrane. This process initializes the transcytosis of the receptor–peptide complex 
in vesicles until the peptide is released at the abluminal membrane. Well known 
compounds for receptor-mediated transport are transferrin and insulin (Figure 5.2d) 
(Xiao and Gan, 2013). Adsorptive transcytosis is the main transport system for 
soluble plasma protein such as albumin. Cationized albumin interacts with the 
luminal membrane for vesicular transport through the EC (Figure 5.2e).  
 
5.1.1.4 Mediators of BBB breakdown 
 
Disturbances of barrier function were shown to be associated with diverse CNS 
diseases (Brown and Davis, 2002; Chodobski et al., 2012; Sweeney et al., 2018). 
Since usually several factor are involved in BBB disruption upon CNS diseases, 
inflammation and important inflammatory mediators such as increased matrix 
metalloproteinase activity and hypoxia are discussed in the following (Kaur and Ling, 
2008; Varatharaj and Galea, 2017). 
 
5.1.1.4.1 Inflammation 
CNS inflammation is highly associated with disease expression and increased BBB 
permeability. One possibility for the systemic induction of inflammation is the 
application of the immunogenic, bacterial component lipopolysaccharide (LPS) 
(Varatharaj and Galea, 2017). LPS challenging of bovine ECs causes a reduction in 
barrier resistance, which might be due to increased EC eicosanoid production (de 
Vries et al., 1996). Eicosanoids are oxidized fatty acids that are produced by the 
enzyme cyclooxygenase and function in cell signaling such as regulation of 
inflammation and control of blood pressure (Spector, 1989). Furthermore, 
cyclooxygenase activity can be influenced by diverse stimuli such as cytokines 
abundance (de Vries et al., 1997), which makes LPS a suitable model to investigate 
early changes during inflammation. In response to in vivo LPS treatment, increased 
tracer penetration was associated with the translocation of occludin and ZO-1 from 
the EC membrane into the cytosol without any alteration in claudin-5 (Banks et al., 




pericyte and astrocyte function, since co-cultures did not provide an ameliorating 
effect. However, depending on the applied LPS dosage, endothelial cell death 
(Karahashi et al., 2009) as well as astrocyte loss (Cardoso et al., 2015) were 
reported. LPS treatment of a human EC line results in increased expression of MMP-
2 and induction of the p38MAPK/JNK pathways which lead to decreased mRNA 
levels and protein abundance of occludin (Qin et al., 2015). Pro-inflammatory 
cytokines are produced by diverse brain cells such microglia, astrocytes, and ECs 
upon inflammation. The predominant cytokines during CNS inflammation and injury 
that have been studied in the context of BBB damage are tumor necrosis factor 
(TNF), interleukin-1 (IL-1), and interleukin-6 (IL-6) (de Vries et al., 1997). In vitro 
application of TNF, IL-1 and IL-6 on primary ECs caused the downregulation of 
claudin-5 m-RNA (Camire et al., 2015) with involvement of the PI3K/AKT pathway 
(Camire et al., 2014). Additionally, it has been shown that occludin is internalized via 
caveolin-1-dependent mechanism upon TNFα signaling (Marchiando et al., 2010) 
Application of the cytokine, interleukin 17 (IL-17), leads to a decreased abundance 
of occludin and ZO-1 (Kebir et al., 2007). Il-17 was further shown to induce EC 
reactive oxygen species (ROS) production, resulting in the downregulation of 
occludin (Huppert et al., 2010). IL-1β decreased sonic hedgehog signaling, which is 
important for tight junction expression and increased cytokine production in 
astrocytes, finally causing enhanced BBB permeability (Wang et al., 2014). 
Moreover, the chemokine CCL2 was able to induce internalization of occludin and 
claudin-5 mediated via lipid raft/caveolin-1 endocytosis (Stamatovic et al., 2009). 
Together, CNS inflammation is highly associated with the increase in cytokines, 
dysregulation of BBB maintenance molecules such as sonic hedgehog and induction 
of MMP activation, leading to BBB disruption. 
 
5.1.1.4.2 Matrix metalloproteinases  
Middle cerebral artery occlusion (MCAO), an ischemic stroke model provides a 
suitable model to analyze matrix metalloproteinase (MMP) function on BBB 
dysregulation (Durukan and Tatlisumak, 2007). Mice challenged by MCAO, 
developed BBB disruptions associated with the upregulation of the MMPs (Lenglet 
et al., 2014). Furthermore, rats challenged with MCAO revealed increased mRNA 




phase of BBB disruption, whereas MMP-9 was involved in progression of BBB 
damage. Moreover, increased MMP abundance was associated with claudin-5 and 
occludin degradation including fragments found in astrocytes. Inhibition of MMP 
function by BB-1101 prevented BBB breakdown and preserved tight junction 
structure (Yang et al., 2007). MMP2 was further shown to be directly involved in the 
degradation of occludin, whereas caveolin (Cav-1) induced endocytosis of claudin-5 
caused its dissociation from the cytoskeleton (Liu et al., 2012). Additionally to MMP-
9 function in tight junction degradation in vitro and in vivo (claudin-5, occludin, ZO-
1), MMP-9 was shown to be responsible for the degradation of basal membrane 
components (laminin, collagen, fibronectin) (Lakhan et al., 2013). Taken together, 
MMP activation causes the degradation of tight junction proteins and basal lamina 
components, which leads to increased BBB permeability.  
 
5.1.1.4.3 Hypoxia 
Hypoxia-induced HIF1 signaling was shown to be involved in BBB disturbances 
(Kaur and Ling, 2008). HIF1, the main regulator of hypoxia, contains an oxygen-
inducible α-subunit and a nuclear located subunit Hif1β. Under normoxic conditions 
HIF1α is constantly marked for proteasomal degraded by prolyl hydroxylases (PHD1-
3, genes Egln1-3). Upon hypoxia, the expression of PHD1-3 is inhibited, leading to 
HIF1α stabilization. Consequently, HIF1α can bind to Hif1β to form a functional 
transcription factor that promotes the expression of HIF1 target genes, including 
VEGF (Vascular endothelial growth factor), MMP2 and GLUT1 (Ziello et al., 2007). 
Furthermore, VEGF signaling affects the expression of the tight junction protein, 
occludin (Zhao et al., 2014). In an in vivo approach of posthypoxic reoxygenation, 
BBB function determined by tracing labeled sucrose showed increased permeability 
that was associated with reduced protein abundance of the tight junction proteins 
occludin and ZO-1 with unaltered expression levels (Witt et al., 2003). Hypoxia 
induced reduction in ZO-1 abundance, localization and expression was caused by 
elevated levels of VEGF (Fischer et al., 2002). Further, in an ischaemia model 
hypoxia induction caused disturbances in ZO-1 and claudin-5 localization with 
unaffected occludin abundance. Inhibition of HIF1 with the use of siRNA prevented 
BBB breakdown (Chen et al., 2009). Moreover, hypoxia induced the decrease in 




and occludin after 24h reperfusion (Chen et al., 2012). Taken together, hypoxia 
induces BBB disruption by reducing tight junction protein abundance. HIF1α target 
genes (e.g. VEGF) might provide indication on the mechanism of hypoxia induced 
BBB disruption.  
In summary, BBB disruption can be caused by a variety of factors, including induction 
of pro-inflammatory cytokines, MMP activation, ROS production and hypoxia induced 
HIF1α signaling. In CNS diseases usually several of these factors contribute to 
disease progression and persistent BBB dysfunction.  
 
5.1.1.5 Manipulation of the BBB 
In addition to the development of new pharmaceuticals for CNS diseases, one major 
challenge includes the application of therapeutically relevant concentrations into the 
brain (Pardridge, 2007). Therefore, treatment strategies focused on the manipulation 
of BBB function to increase drug entry for a predictive duration. One of the first 
attempts for the chemical manipulation of BBB function was the osmotic disruption 
of tight junctions by infusion with urea or mannitol (Brightman et al., 1973; Siegal et 
al., 2000). This approach reversibly opened the BBB, but challenges like undesired 
entry of other substances and long-lasting disruption of tight junctions for several 
hours unraveled the disadvantage of the system (Kemper et al., 2004; Kroll and 
Neuwelt, 1998). Analysis of the microvascular brain structure of frogs revealed 
increased permeability after administration of bradykinin, an inflammatory and 
neurovascular mediator (Olesen and Crone, 1986). Mimicking bradykinin function by 
the application of RMP-7, an agonist that binds to the bradykinin receptor localized 
on endothelial cells, revealed opening of the BBB for a shorter time period compared 
to osmotic disruption (Sanovich et al., 1995). In a rat tumor model RMP-7 application 
in combination with the chemotherapeutic agent carboplatin enhanced carboplatin 
entry, which was associated with increased survival (Matsukado et al., 1996). 
Nevertheless, clinical application for cancer therapy with a combination of RMP-7 
and a chemotherapeutical showed unaltered tumor progression in malignant glioma, 
possible due to insufficient RMP-7 dosages (Prados et al., 2003). A synthetically 
modified E-cadherin peptide (His-Ala-Val; HAV) is able to modulate BBB function by 
the inhibition of the interaction between E-cadherin proteins in the intercellular cleft 




already after three minutes treatment with the duration of only one hour. A first report 
of a treatment approach in glioblastoma revealed elevated drug entry into the brain 
(On et al., 2017). For the neurotransmitter glutamate it was shown that it increases 
barrier permeability by the activation of NMDA-receptors, which was prevented by 
the application of an antagonist (Attwell et al., 2010; Vazana et al., 2016). A 
hypothesis for the increased BBB permeability was reported by the enhancement of 
calcium flux and nitric oxide levels within or adjacent to microvascular structures, 
which might lead to reorganization or altered regulation of tight junction proteins. 
Furthermore, NMDA activation via high-intensity magnetic stimulation provided a 
non-invasive tool to manipulate BBB function in rats with an increase in the delivery 
of penicillin to the neural tissue. Moreover, a preclinical trial with malignant glioma 
patients using dynamic contrast-enhanced MRI revealed increased permeability in 
the tumor area, the peritumoral area und even the contralateral hemisphere (Vazana 
et al., 2016). Another approach to enhance drug entry in the CNS is the 
encapsulation of therapeutic agents in biodegradable nanoparticles (Hernández-
Pedro et al., 2013). A major advantage of nanoparticles for drug delivery into the 
CNS is the possibility to engineer labeled nanoparticles that are recognized by 
specific receptors for targeted delivery of e.g. chemotherapeutic drugs for glioma 
therapy (Lee, 2017). A clinical trial of glioblastoma multiforme patients using 
magnetic nanoparticles for targeted thermotherapy in glioma cells with combined 
radiotherapy revealed a median survival of 23 month (Maier-Hauff et al., 2011). The 
extended survival of 23 month compared to the 15 month with a standard treatment 
for glioblastoma multiforme (Stupp et al., 2005) providing future perspectives for 
nanoparticle therapy in glioblastoma treatment.  
Interestingly, volatile anesthetics such as isoflurane and sevoflurane were shown to 
manipulate BBB function (Acharya et al., 2015; Tétrault et al., 2008), which are 
described in the next chapter (5.1.2 Isoflurane).  
 
5.1.2 Isoflurane 
In addition to the above described mechanism of BBB manipulation, volatile 
anesthetic agent such as isoflurane and sevoflurane were shown to increase BBB 
permeability. Isoflurane is a widely used inhalational anesthetic agent of the 




in a dose dependent manner (1% and 3% isoflurane concentration) (Tétrault et al., 
2008). Isoflurane and sevoflurane anesthesia were shown to cause BBB disruption 
in elderly rats (1-3% isoflurane anesthesia for 3h) (Acharya et al., 2015). 
Furthermore, sevoflurane anesthesia altered luminal endothelial cell surface 
morphology with indications for endothelial cell death. BBB disruption was persistent 
even after 24h recovery. These results are supported by the finding that isoflurane 
applied in elderly mice increased the abundance of pro-inflammatory cytokines such 
as TNF, Il-6 and Il-1β (1.4% isoflurane for 2h) (Wu et al., 2012). Further it was shown 
that isoflurane enhances HIF1 signaling in primary hippocampal neurons (1.2% 
isoflurane for 12 h) (Chai et al., 2016). These findings are in accordance with the 
assumption that isoflurane can cause neurotoxicity (Jiang et al., 2012; Lemkuil et al., 
2011). Moreover, during sevoflurane and isoflurane anesthesia in an experimental 
brain trauma model in mice tight junction abundance of ZO-1 and claudin-5 was 
decreased, whereas tight junctions of healthy control animals were unaffected (1.5% 
isoflurane or 3.5% sevoflurane for 20min) (Thal et al., 2012). Aged rats treated with 
isoflurane showed decreased expression of occludin (1.5% isoflurane for 4h) (Cao 
et al., 2015). A mechanism of isoflurane function in BBB breakdown has been 
postulated by Zhao and others in an in vitro approach, which showed that isoflurane 
increased the abundance of HIF1α inducing the expression of the target genes Vegf 
and Tgf-β3 (0.5-2.5% isoflurane for 3-6h). In the following, VEGF and TGF-β3 cause 
the reduction of occludin expression and internalization, respectively (Zhao et al., 
2014).  
Taken together, isoflurane (and sevoflurane) modulate BBB function by targeting 
tight junction stability. Furthermore, the concentration of the anesthetic agent and the 
duration of the treatment highly influence the extent of the permeability and the 
impact on tight junction stability. For example 1.5% isoflurane anesthesia for 4h 
decreased occludin expression (Zhao et al., 2014), whereas 20min of 1.5% 
isoflurane treatment showed unaffected tight junctions (Thal et al., 2012). Therefore, 
highly regulated use of isoflurane anesthesia might provide a suitable system to 





5.1.3 Glioblastoma multiforme 
5.1.3.1 Disease and therapy 
Primary brain tumors, referred to as gliomas, are named after their originating cell 
like e.g. astrocytoma, oligodendrogliomas, ependymomas and glioblastoma. In 
general, gliomas are classified into four categories: grade I, II, III and IV by the WHO 
(World Health Association) according to their growth pattern and malignity. 
Glioblastoma multiforme (GBM) is the most common form of grade IV brain tumors, 
which is characterized by an aggressive growth pattern, enhanced tumor outgrowth 
into surrounding tissue, autonomous vasculature and a necrotic tumor center (Davis, 
2016). The incidence to develop a glioblastoma is 3.2/100.000 population with a poor 
prognosis of a median survival of 15 month (Hanif et al., 2017). GBMs are mainly 
spontaneous arising tumors and only 1% of GBMs are reported to be hereditary 
(Schwartzbaum et al., 2006). Genetic diseases such as tuberous sclerosis or multiple 
endocrine neoplasia as well as physical brain injuries were shown to cause the 
development of glioma (Urbanska et al., 2014). Further, increased expose to ionizing 
radiation provides a risk factor for the development of GBM (Hanif et al., 2017). GBM 
are developed at all ages with 64 years as the average age of diagnosis (Ostrom et 
al., 2013). The standard treatment for GBM is surgical resection followed by 
radiotherapy and chemotherapy; however additional chemotherapy only prolonged 
patients’ survival of about 3 month in contrast to radiotherapy alone (Stupp et al., 
2005).  
The most common used chemotherapeutic agent is temozolomide, since it is able to 
pass the BBB (Koukourakis et al., 2009). Temozolomide is hydrolyzed resulting in 
the active form methyl-triazeno imidazole-carboxamide (MTIC), which acts by 
methylation of DNA causing cytotoxicity (Newlands et al., 1997). Due to the short 
half-life of temozolomide (1.5h/plasma) (H.-L. Liu et al., 2014) systemic 
administration needs to be performed at high doses, which cause varies side effects, 
such as headache and nausea (Zhang and Gao, 2007). Furthermore, as stated 
above, temozolomide only shows minor benefit on patients’ survival. Another 
antineoplastic drug used in clinical trials is the intercalating agent, carmustine, which 
acts by crosslinking DNA strands that blocks DNA repetition. After surgical resection 
of the tumor, carmustine incorporated in a degradable reservoir enables local 




patients with the undesired side effect of increased CSF leak, which could facilitate 
infections (Nagpal, 2012; Westphal et al., 2003). A well-known chemotherapeutic 
agent is cisplatin that is successfully used to treat diverse cancer types outside the 
CNS, such lung or ovarian cancer (Shaloam Dasari and Paul Bernard Tchounwou, 
2015). Cisplatin functions similar to carmustine, by crosslinking DNA strands thereby 
inhibiting DNA repetition and repair. Undesired side effects like nephrotoxicity and 
especially the disability to penetrate functional BBB illustrate the weakness of 
cisplatin for glioblastoma treatment (Shaloam Dasari and Paul Bernard Tchounwou, 
2015). However, another study postulated efficacy against brain tumors e.g. 
medulloblastoma (Gottardo and Gajjar, 2008). 
In addition to the development of new chemotherapeutic agents, the main challenge 
in the treatment of GBM is the achievement of effective doses within the tumor and 
the surrounding tissue, since GBM are vulnerable for spreading and reoccurrence 
(Cooper et al., 2015).  
 
5.1.3.2 Gl261 glioblastoma cell line  
Spontaneous development of CNS tumors in rodents is extremely rare (Fitzgerald et 
al., 1974; Fraser, 1971). Animal models include: transgenic models, virus-induced 
tumors, transplantation of human glioma cells in immunocompromised mice and 
transplantation of murine glioma cell line in syngeneic mouse models (Peterson et 
al., 1994). The main benefit of transplantation studies using a glioma cell line is the 
high reproducibility with a predictable tumor growth pattern. Transplantation studies 
of a murine glioma cell line in a syngeneic mouse model further provides the 
advantage to avoid the additional treatment of mice with immunocompromising 
agents.  
A well-known cell line for transplantation studies is the Gl261 mouse glioblastoma 
cell line that was established using chemical induction with methylcholanthrene 
(Ausman et al., 1970). Intracranial implanted C57BL/6 mice with 1x 105 implanted 
Gl261 cells showed an invasive and angiogenic growth behavior with a medium 
survival of 25 days (Szatmári et al., 2006). Histological analysis of Gl261 tumors 
revealed a tumor with irregularly shaped borders and a few migrating tumor cells into 
surrounding tissue (Newcomb and Zagzag, 2009). However, the Gl261 tumor model 




spontaneously arisen glioma in human patients (Maes and Van Gool, 2011). Gl261 
cells that express the fluorescent marker GFP provided the possibility to analyze 
histologically tumor size and single cell outgrowth in Gl261 implanted tumor mice  
 
5.1.4 Aim of the study 
GBM is the most common malignant brain tumor that is characterized by an invasive 
growth pattern, autonomous vasculature and a necrotic tumor center (Davis, 2016). 
Standard treatment for GBM includes surgical resection followed by radiotherapy and 
chemotherapy with only minor impact on patients’ survival. The major challenge in 
the chemotherapeutic treatment of patients is the application of therapeutically 
relevant concentrations into the brain (Pardridge, 2007).  
In this study the first aim was to analyze the potential of the volatile anesthetic agent 
isoflurane to manipulate BBB permeability. Therefore, biochemical quantification of 
tracer entry was performed with different isoflurane concentrations. Additionally, 
transcriptional changes were investigated after short-term and long-term isoflurane 
treatment. Moreover, late effects after short-term isoflurane treatment were 
analyzed. Analysis of tight junction protein abundance was performed by antibody 
labeling. In the second part, Gl261 glioblastoma cells were transplanted into wildtype 
mice. The chosen cell line was already proved to serve as a suitable model system 
for GBM research (Szatmári et al., 2006). Isoflurane induced enhancement of tracer 
extravasation in Gl261 cells transplanted tumor mice was quantified. In the third part, 
we focused on the development of a new therapeutic approach for GBM by the use 
of a combined treatment of cisplatin with isoflurane anesthesia to increase drug entry 
into the brain of Gl261 transplanted mice. After transplantation of Gl261 cells, mice 
were treated two times with the chemotherapeutic agent cisplatin with and without 
isoflurane anesthesia. Tumor growth was monitored twice by magnetic resonance 
imaging. For the readout of the therapeutic benefit, tumor volume, T-cell infiltration, 
tumor cell viability and the invasive phenotype of Gl261 cells was investigated. With 
our experimental design we wanted to answer the questions (1) whether isoflurane 
anesthesia can be used to manipulate BBB function in a confined period (2) whether 
isoflurane treatment can increase tracer/ drug entry into the brain of tumor mice and 














5.2.1 Dose-dependent increase in BBB permeability after treatment with 
volatile isoflurane 
The controlled flux of metabolites and the restrictive passage of biomolecules 
between the periphery and central nervous system is mediated by the BBB. Today, 
different systems to modulate BBB function have been studied with several 
advantages and disadvantages (Attwell et al., 2010; Bartus et al., 1996; Kemper et 
al., 2004; Lee, 2017; On et al., 2014; Vazana et al., 2016) (see chapter 5.1.1.5). One 
novel approach to modulate BBB function might be by the use of the anesthetic agent 
isoflurane. It has been shown that cats under isoflurane anesthesia exhibit an 
impairment of the BBB (Tétrault et al., 2008). The present work represents the 
investigation of isoflurane as a tool to modulate BBB function and further to enhance 
drug delivery in a glioblastoma mouse model. 
First, we needed to analyze whether isoflurane treatment of wildtype mice increases 
tracer delivery into the brain. Therefore, Evans blue was i.v. injected into the tail vein 
of wildtype mice and allowed to circulate with 1%, 4% isoflurane treatment or oxygen 
for 1h. Interestingly, the results indicate that isoflurane treatment increases Evans 
blue extravasation into the brain (Figure 5.3a). Furthermore, 4% isoflurane treatment 
seemed to be more effective to enhance tracer extravasation than 1% isoflurane. 
Next, to analyze the duration and the indicated dose-response of isoflurane 
treatment, a biochemical quantification of Evans blue extravasation was performed 
with a novel developed approach (Berghoff et al., 2017a). Notably, the results 
revealed a significant dose-dependent increase in blood-brain-barrier permeability of 
isoflurane treated animals (O2 3.1±0.05 EB µg/g dry weight compared to 1% 
isoflurane 4.2±0.32 and 2.5% isoflurane 5.7±0.27) (Figure 5.3c). Further, Evans blue 
application after the withdrawal of isoflurane showed an extravasation level 
comparable to oxygen treated controls (O2 3.1±0.05 EB µg/g dry weight compared 
to 3.1±0.48 after the withdrawal of isoflurane). The brain water content, as a measure 
of edema formation, was unaffected by isoflurane treatment, excluding edema as a 





Figure 5.3I Dose dependent increase of Evans blue extravasation in isoflurane treated 
animals. (a) Evans blue extravasation on sections of the striatum. Control animals were treated 
with oxygen. Isoflurane anesthesia was applied in two concentrations, 1% and 4% isoflurane for 
the duration of 1h. (b) Treatment scheme for the biochemical quantification assay of Evans blue 
extravasation after isoflurane application. Evans blue extravasation was quantified for 1% and 
2.5% isoflurane as well as under oxygen treatment alone. Furthermore, Evans blue extravasation 
was analyzed after the withdrawal of 2.5% isoflurane. Isoflurane treatment was performed as 
followed: The mouse was put to sleep with 4% isoflurane for 2min. Afterwards the respective 
treatment with 1% or 2.5% isoflurane was performed for 28min followed by 2min oxygen to allow 
the mouse to wake up and recover from anesthesia. Evans blue was allowed to circulate for the 
total duration of 1h. For the isoflurane recovery experiment, Evans blue was applied directly after 
the recovery of the mouse with 2min oxygen. For comparable results, Evans blue circulation was 
performed for 1h. (c) Biochemical quantification of Evans blue extravasation in control and 
isoflurane treated mice (n=5-9). One-way-ANOVA with Tukey’s multiple comparison test was 
performed (d) Quantification of brain water content in control and isoflurane treated mice (n= 4-
5). One-way-ANOVA with Tukey’s multiple comparison test was performed. Differences were 
considered significant with a P-value of *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001; ns = 
not-significant. (Evans blue quantification was done together with Stefan Berghoff). 
 
These data indicate that 2.5% isoflurane treatment modulates BBB tracer application 
for the duration of 30min (referred to as short-term) in a sufficient manner. 
Additionally, tracer application after the withdrawal of isoflurane revealed an 






5.2.2 BBB modulation after short-term isoflurane treatment functions via a 
hypoxia independent pathway 
The BBB is mainly formed by endothelial cells which are connected to each other via 
belt-like tight junctions. Alterations of tight junction abundance or distribution disrupt 
BBB function (Coisne and Engelhardt, 2011). It has been shown that long-term 
isoflurane treatment in an in vitro approach stabilizes the main regulator of hypoxia 
Hif1α, which triggers Vegfα and Tgfβ3 expression and this affects the expression of 
the tight junction protein, occludin (Ocln) (Zhao et al., 2014). Therefore, it is highly 
presumable that long-term isoflurane treatment in vivo enhances hypoxia induced 
gene expression. In contrast acute transcriptional changes are unknown. Therefore, 
we wanted to analyze early changes in the transcriptional expression level of mice 
treated with 2.5% isoflurane for 30min (short-term). Three additional control groups 
were added: (1) the first cohort was treated for 30min with the carrier gas oxygen (2) 
the second group was treated with 2.5% isoflurane for 3h (long-term) as positive 
control (3) the third cohort was treated with 2.5 % isoflurane for 30min followed by 
2.5h recovery and served as a control group for possible long-term effects.  
After long-term isoflurane treatment, the expression of Cldn5 was significantly 
increased (Cldn5 oxygen 1.0±0.09 rel. exp. and after 3h isoflurane 2.1±0.41) and 
ZO-1 (Tjp1) was slightly downregulated (Tjp1 oxygen 1.0±0.04 rel. exp. and after 3h 
isoflurane 0.71±0.15) (Figure 5.4a). Occludin expression was unaltered, but Hif1α 
signaling changed after long-term isoflurane treatment with an increase in both Vegfα 
and Tgfβ3 expression (Vegfα: oxygen 1.0±0.04 rel. exp. and after 3h isoflurane 
1.8±0.28 and Tgfβ3: oxygen 1.0±0.05 and after 3h isoflurane 1.7±0.17), indicating 
hypoxic conditions (Figure 5.4b). Under normoxic conditions Hif1α is marked for 
degradation by proline-hydroxylases 1-3 (gene Egln1-3), whereas during hypoxia the 
expression of these enzymes is inhibited. Therefore, the expression level of Egln1-3 
was tested showing decreased expression of all Egln genes for the 3h time-point 
(Figure 5.4c). Additionally after long-term treatment, Hif1α expression was 





Figure 5.4I Expression level of tight junction proteins, Hif1α signaling, MMPs and pro-
inflammatory cytokines in isoflurane treated animals. (a) Quantitative RT-PCR on striatum 
and thalamus determining expression of the tight junction proteins, Cldn5, Ocln and Tjp1, (b) 
markers for hypoxia/Hif1a signaling, Hif1α, Vegfα and Tgfβ3 (c) Hif1α degrading enzymes Phd1-
3 (Egln1-3) (d) and markers for MMPs and pro-inflammatory cytokines, Mmp2, Mmp9, Il6 and 
Tnfα (n= 5-18). One-way ANOVA of each gene with Tukey’s multiple comparison test was 
performed and normalized to RplpO. Furthermore, treatment cohorts were normalized to oxygen 
treated wildtype controls. Differences were considered significant with a P-value of *, P<0.05; **, 
P<0.01; ***, P<0.001; ****, P<0.0001; ns = not-significant. 
 
In summary these data suggest hypoxia induced changes in the expression level of 
tight junction genes after long-term isoflurane treatment. Claudin5 and ZO-1 showed 
alterations in the expression level after long-term isoflurane treatment. Occludin 
expression was unaltered in contrast to published data, which might reflect an earlier 




et al., 2014). Since Hif1α is highly regulated on protein level, western blot 
experiments must be performed to confirm this hypothesis.  
In contrast to the 3h time-point, the expression level of the tight junction proteins 
claudin5, ZO-1 and occludin was unaltered after 30min isoflurane treatment (Figure 
5.4a). Interestingly, hypoxia induced alterations in gene expression were not 
detectable, suggesting a different mechanism for BBB modulation after short-term 
isoflurane treatment compared to long-term treatment (Figure 5.4b/c). 
Matrix metalloproteinases (MMP) are involved in BBB disruption in diverse CNS 
diseases (Rempe et al., 2016). MMPs function in the degradation of basement 
membrane proteins and tight junction proteins (Feng et al., 2011). Long-term 
isoflurane treatment has been shown to increase the expression of pro-inflammatory 
cytokines e.g. tumor necrosis factor α (Tnfα) and interleukin-6 (Il6) (Wu et al., 2012). 
Furthermore, pro-inflammatory cytokines were involved in disruption of occludin (Lv 
et al., 2010; Rochfort and Cummins, 2015). To investigate whether pro-inflammatory 
cytokines and MMPs contribute to isoflurane induced BBB modulation, 
transcriptional changes in the expression of Mmp2, Mmp9, Il6 and Tnfα were 
analyzed (Figure 5.4d). Short-term isoflurane treatment of 30min as well as extensive 
isoflurane treatment for 3h revealed unaltered expression levels of MMPs and pro-
inflammatory cytokines. These data imply that the isoflurane induced increase in 
BBB permeability does not function via the upregulation of pro-inflammatory 
cytokines or MMPs. 
 
5.2.3 Decreased protein abundance of occludin and claudin5 after short-term 
isoflurane anesthesia 
The expression level of tight junction proteins after short-term isoflurane treatment 
was unaltered, but the Evans blue extravasation assay showed increased tracer 
permeability. Therefore, we wanted to address the question, whether the abundance 
of tight junction proteins is decreased after isoflurane treatment. Pilot stainings of 
claudin5, ZO-1 and occludin on brain section of 30min and 3h isoflurane treated 
animals were performed and compared to oxygen treated controls. Preliminary 
results revealed reduced abundance of occludin and claudin5 after long-term 






Figure 5.5I Tight junction staining of isoflurane treated mice. Pilot tight junction staining’s 
were performed for single animals. Mice were treated for 30min with oxygen or isoflurane for 
30min and 3h. Occludin (Ocln), claudin5 (Cldn5) and ZO-1 were depicted in green and the blood 
vessel is outlined in red. Scale bar 10µm. 
 
Notably, already after short-term isoflurane treatment, occludin protein abundance 
showed a strong reduction compared to oxygen treated control mice and further 
claudin5 seemed to be slightly reduced. Stainings of ZO-1 revealed unaltered ZO-1 
intensity in isoflurane treated mice compared to oxygen treated controls. 
Nevertheless, ZO-1 positive area per vessel (marked in red) seem to be reduced. 
Further staining’s need to be performed to elucidate the abundance of ZO-1 in 
isoflurane treated animals.  
Taken together these results suggest that isoflurane treatment decreases the 
abundance of occludin and claudin5, starting with 30min anesthesia and proceeding 
in the tested 3h time point. 
 
5.2.4 Increased BBB permeability in a tumor mouse model after short-term 
isoflurane treatment 
We showed that 2.5% isoflurane treatment for 30min provided the perfect tool to 
modulate BBB function for a restrictive duration to enhance Evans blue extravasation 
into the brain. Treatment strategies in the field to brain tumor research focus on 
applications to modulate BBB function to increase the permeability for 
chemotherapeutics (see chapter 5.1.1.5) (Kemper et al., 2004). Therefore, we 
wanted to investigate whether isoflurane can be used to increase in vivo 
extravasation of Evans blue in a brain tumor model. For that purpose, a glioblastoma 
mouse model was established in our laboratory (in collaboration with Dr. Petra 




Hülper) in the right hemisphere and the tumor was allowed to grow for 10 days. At 
day 10 mice were i.v. injected with Evans blue and treated either for 30min with 2.5% 
isoflurane or vehicle. Afterwards, brains were divided in right hemisphere (tumor) and 
contralateral, left hemispheres (w/o tumor) (Figure 5.6a). Further mice without 
transplantation served as control.  
Previously it has been reported that the tumor area of Gl261 implanted cells in mice 
was permeable for Evans blue entry already after two weeks implantation (Leten et 
al., 2014). Therefore, elevation in Evans blue abundance in the tumor hemisphere of 
oxygen treated mice was expected (tumor hemisphere: control 2.33±0.04 EB µg/g 
dry weight compared to oxygen 3.3±0.08) (Figure 5.6b). However, this effect was not 
detected in the contra hemisphere (contralateral hemisphere: control 2.5±0.06 EB 
µg/g dry weight compared to oxygen 2.84±0.14). Interestingly, mice treated with 
isoflurane for 30min displayed not only an increase in Evans blue permeability in the 
contra hemisphere, but also a further increase in the tumor hemisphere (contralateral 
hemisphere: 3.69±0.09 EB µg/g dry weight tumor hemisphere 4.65±0.06) (Figure 
5.6b).  
These data suggest that 30min 2.5% isoflurane treatment might be feasible to 
enhance the delivery of chemotherapeutics not only to the tumor mass, but further to 
the whole brain tissue. 
In order to analyze the influence of isoflurane on Gl261 cells, a WST-1 (water soluble 
tetrazolium salt) assay was performed, in which cell viability was quantified 
(performed by Nina Gerndt). The viability of Gl261 cells was highly affected with 1% 
isoflurane treatment (Figure 5.6c). Therefore, an isoflurane treated control group was 
added for later described experiments.  
The cytostatic agent, cisplatin, is a widely used drug for the treatment of diverse solid 
cancer types, like lung or testicular carcinoma. It acts by DNA crosslinking and 
therefore induces apoptosis of any proliferating cell (Shaloam Dasari and Paul 
Bernard Tchounwou, 2015). To investigate the lowest feasible concentration to treat 
Gl261 cells, a dose-response assay with the use of the WST-1 system was 
performed (Nina Gerndt). The results revealed that cisplatin concentrations of 
0.5µg/ml or lower showed unaltered Gl261 viability, whereas concentration of 5µg/ml 
or higher seemed to be highly efficient (Figure 5.6d). We decided for 2.5µg/ml as the 






Figure 5.6I Isoflurane treatment increased BBB permeability in a glioblastoma mouse 
model. (a) Treatment scheme of brain tissue sectioning for the Evans blue extravasation assay 
(b) Biochemical quantification of Evans blue extravasation in control (O2) and isoflurane treated 
mice (n= 3-4) implanted with Gl261 glioblastoma cells. One-way-ANOVA with Tukey’s multiple 
comparison test was performed for the tumor hemisphere and the contralateral site. Results were 
compared to mice without tumor transplantation (b) WST-1 viability test of isoflurane treated 
Gl261 glioblastoma cells (n= 4). H2O2 served a positive control. (c) Dose-response curve of 
GL261 cells treated with cisplatin (n= 3). WST-1 system was used. Significance was quantified 
with one-way-ANOVA with Tukey’s multiple comparison test. H2O2 served a positive control. 
Differences were considered significant with a P-value of ****, P<0.0001; ns = not-significant. 
(WST-1 assay was performed by Nina Gerndt; biochemical Evans blue quantification was done 






5.2.5 Decreased tumor volume in cisplatin and isoflurane treated mice 
Next, we wanted to investigate the impact of isoflurane initiated BBB modulation on 
the therapeutic action of cisplatin in our glioblastoma mouse model. GFP expressing 
Gl261 glioma cells were intrathecal implanted in the right hemisphere of wildtype 
mice. Tumor growth was controlled by MRI imaging techniques on day 7 (in 
collaboration with the Biomedizinische NMR Forschungs GmbH, Prof. Jens Frahm). 
Two treatment time-points were chosen on day 9 and day 11. Mice were i.v. injected 
with either cisplatin (3mg/kg cisplatin) or saline. Afterwards, mice of the isoflurane 
cohorts were treated with 2.5% isoflurane for 30 min under constant control of body 
temperature and respiration. Tumor volume was measured with a second MRI on 
day 13. On day 14 mice were perfused and immunohistological aspects of the 
different treatment paradigms were analyzed on brain tissue (Figure 5.7a). The 
experimental design comprised four treatment cohorts: (1) i.v. saline (2) i.v. saline 
with 2.5% isoflurane treatment for 30min (3) i.v. cisplatin (4) i.v. cisplatin with 2.5% 
isoflurane anesthesia for 30min.  
Quantification revealed that isoflurane treatment without cisplatin showed unaltered 
tumor volume (saline: 3.05±0.26mm2 compared to isoflurane 3.39±0.14mm2) (Figure 
5.7b). This suggests a different effect of isoflurane on the implanted Gl261 cells 
compared to the cultivated cells, which already showed decreased viability with 1% 
isoflurane treatment (Figure 5.6b). 
Mice treated with cisplatin alone showed a slightly reduced tumor volume, but did not 
reach significance (saline: 3.05±0.26mm2 compared to cisplatin 2.58±0.23mm2). 
Notably, application of the combined treatment of cisplatin and isoflurane decreased 
significantly the tumor volume compared to all other tested groups animals by almost 
50% (cisplatin + isoflurane 1.71±0.19mm2).  
In summary, quantification of tumor volume showed only a small effect for cisplatin 
treatment alone as expected. Since cisplatin is unable to pass the BBB, the treatment 
was limited to the BBB compromised tumor center. In contrast, the combined 
treatment with cisplatin and isoflurane highly decreased tumor volume. These results 
suggest that isoflurane treatment increased the penetration of cisplatin into whole 






Figure 5.7I Reduced tumor volume in cisplatin and isoflurane treated glioblastoma mice. 
(a) Treatment protocol of the glioblastoma mouse model. Four treatment cohorts were analyzed 
(1) i.v. saline (2) i.v. saline with isoflurane (3) i.v. cisplatin (4) i.v. cisplatin with isoflurane (n= 6-
13). (b) Quantification of MRI measurements: T1-weighted MRI was used to quantify tumor 
volume. Single images were analyzed, positive tumor area selected and tumor volume was 
quantified with Amira Software. Significance was quantified with one-way-ANOVA with Tukey’s 
multiple comparison test between all tested cohorts. MRI of one representative cisplatin and one 
cisplatin + isoflurane treated animal (performed by Thomas Michaelis, Takashi Watanabe and 
Sabine Höfer, Biomedizinische NMR Forschungs GmbH, Prof. Jens Frahm). Differences were 
considered significant with a P-value of *, P<0.05; ***; ns = not-significant. 
 
5.2.6 Increased T-cell infiltration in the surrounding tumor area of cisplatin 
and isoflurane treated mice 
It is known that human glioblastoma develop strategies to escape immune 
surveillance (Razavi et al., 2016). Therefore, quantification of T-cell numbers served 






Figure 5.8I Increased numbers of T-cells in the tumor surrounding of cisplatin and 
isoflurane treated mice. Quantification of CD3 positive cells in tumor tissue and in tumor 
surrounding (tumor surrounding = + 50 % of the tumor area) of Gl261 implanted mice treated with 
cisplatin or saline with or without additional 2.5% isoflurane treatment for 30min (n= 3-7). The 
tumor mass is outlined in red One-way-ANOVA with Tukey’s multiple comparison test was 
performed for the tumor area and the tumor surrounding between treatment cohorts. Differences 
were considered significant with a P-value of *, P<0.05; ns = not-significant. Scale bar 200µm, 
selection 20µm. 
 
CD3 (cluster of differentiation 3) staining was used as a marker for the T-cell lineage 
of tumor-infiltrating lymphocytes (Chetty and Gatter, 1994). To address the question 
if isoflurane treatment extended cisplatin delivery from the tumor mass to the tumor 
surrounding, CD3 positive cells within the tumor mass and the surrounding area were 
analyzed. A slight, but not significant increase in T-cell infiltration in the tumor mass 
of both cisplatin treated groups was detected as expected (saline: 658.8±81.9 
CD3+/mm2 compared to cisplatin 1050±137.8 and cisplatin + isoflurane 
1178±174.7). Notably, only the combined treatment of cisplatin and isoflurane 
showed elevated numbers of CD3 positive cells within the tumor surrounding (saline: 
240.4±35.4 CD3+/mm2 compared to cisplatin + isoflurane 371±38.3) (Figure 5.8). In 
summary, both cisplatin cohorts revealed elevated immune response within the 
tumor area. Furthermore, the combined treatment of isoflurane and cisplatin caused 
an increased immune responsiveness in the tumor surrounding. This increased 
immune response in the combined cohort suggests that the modulation of BBB 




5.2.7 Reduced tumor cell viability in the combined treatment of cisplatin and 
isoflurane 
Gl261 cells implanted in wildtype mice developed a highly proliferative phenotype in 
which the untreated tumor approximately doubled the size within six days (data not 
shown). To further address the question, whether the combined treatment of cisplatin 
and isoflurane shows reduced tumor proliferation, EdU (5-ethynyl-2′-deoxyuridine) 
was injected 16h prior to perfusion. Combined stainings of EdU for proliferating cells 
and TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling) for 
apoptotic cells were performed to determine the viability of the tumor cells. The 




Figure 5.9I Reduced proliferation in cisplatin and isoflurane treated animals. Quantification 
of TUNEL and EdU positive cells in the tumor area (n= 6-7) of Gl261 implanted mice treated with 
cisplatin or saline with or without additional 2.5% isoflurane treatment for 30min. One-way-
ANOVA with Tukey’s multiple comparison test was performed between all tested cohorts. 
Differences were considered significant with a P-value of **, P<0.01; ***, P<0.001; Scale bar 
200µm, selection 20µm. 
 
The analysis revealed increased numbers EdU positive cells over TUNEL positive 
cells in both saline treated groups as well as in the cohort treated with cisplatin alone 




cisplatin 0.54±0.09) (Figure 5.9). These results indicate a highly proliferative 
phenotype for the cisplatin group as expected, since treatment is limited to the BBB 
comprised tumor core. Interestingly, the combined treatment of cisplatin and 
isoflurane showed equal numbers of apoptotic and proliferative cells (cisplatin + 
isoflurane 1.07±0.12 TUNEL/EdU). These results suggest enhanced cisplatin 
treatment within the whole tumor area, when isoflurane treatment was performed.  
 
5.2.8 Decreased tumor cell migration in cisplatin and isoflurane treated mice 
Glioblastoma multiforme is a very aggressive, rapidly growing brain tumor with 
intrinsic resistance to radio- and chemotherapy and therefore a poor prognosis for 
patients. New treatment approaches are currently under investigation with the main 
purpose to target tumor motility and prevent the tumor from spreading. 
 
 
Figure 5.10I Decrease in migrating tumor cells in cisplatin + isoflurane treated mice. 
Quantification of GFP positive tumor cells in Gl261 implanted mice treated with cisplatin or saline 
with or without additional 2.5% isoflurane treatment for 30min (n= 8-11). Significance was 
quantified with one-way-ANOVA with Tukey’s multiple comparison test. Differences were 
considered significant with a P-value of *, P<0.05; Scale bar 200µm. 
 
GFP (Green fluorescent protein) expressing Gl261 cells were used to address the 
question, whether isoflurane can be used as a tool to attack specifically migrating 




autofluorescence, GFP stainings on vibratome brain sections were performed to 
target all GFP expressing tumor cells. GFP positive tumor cells within the 
surrounding of the tumor area (50% of the tumor area) were quantified, including 
detached ones and cells that were still in contact with the tumor, but start to invade.  
The obtained data revealed that the number of migrating tumor cells in both saline 
cohorts and the cisplatin group showed a comparable number of GFP positive cells 
in the tumor surrounding (saline: 219.6±35.2 GFP+/mm2 compared to 
saline/isoflurane 231.4±42.7 and cisplatin 224.4±35.12) (Figure 5.10). Notably, the 
combined treatment of cisplatin and isoflurane abolished tumor cell migration by 
about 70% (cisplatin + isoflurane 87.7±15.9 GFP+/mm2) indicating that isoflurane 
serves as a suitable tool to increase the permeability of cisplatin in the tumor 
surrounding. With the use of isoflurane we are able to increase the treatment area of 















5.3.1 Quantification of dose-dependent isoflurane BBB manipulation 
Isoflurane anesthesia was shown to increase Evans blue brain entry in a dose-
dependent manner (Tétrault et al., 2008). Using a new sensitive, biochemical 
quantification of Evans blue extravasation (Berghoff et al., 2017a), we were able to 
quantify the indicated dose-response and further achieve an estimation about the 
suitable duration for therapeutic intervention of isoflurane induced BBB manipulation. 
Therefore, the treatment of 30min with 2.5% isoflurane increased BBB permeability 
of Evans blue almost two-fold. For the first time we were able to quantify increased 
BBB permeability after short-term isoflurane treatment, in contrast to previous 
studies, which showed in vivo changes of BBB permeability only after three hours or 
more (Acharya et al., 2015; Cao et al., 2015). Furthermore, our results show that 
Evans blue application after the withdrawal of isoflurane revealed an extravasation 
level comparable to untreated controls, indicating reversible opening of BBB. These 
results suggest the applicability of isoflurane treatment for a temporarily confined 
manipulation of BBB function, with special focus on 2.5% isoflurane treatment for 
30min. 
 
5.3.2 Isoflurane mechanism of BBB modulation  
To investigate the mechanism and safety of our treatment approach of 30min 2.5% 
isoflurane (in the following referred to as short-term treatment), we decided to 
compare it to 3h isoflurane treatment (referred to as long-term treatment), which was 
already investigated in previous studies (Acharya et al., 2015; Chai et al., 2016; Zhao 
et al., 2014). As expected long-term isoflurane treatment reduced the protein 
abundance of the tight junction proteins, occludin, claudin-5 with further indications 
of ZO-1 alterations. Moreover, the expression level of claudin-5 was highly 
increased, which might suggest a compensatory mechanism to increase tight 
junction abundance at the compromised BBB. In accordance with in vitro studies 
(Chai et al., 2016; Zhao et al., 2014), long-term in vivo isoflurane treatment induced 
transcriptional changes of the Hif1α signaling pathway. The expression level of Hif1α 




enzymes involved in the degradation process of Hif1α (Egln 1-3) revealed reduced 
mRNA abundance. In addition, Hif1α target genes (Vegf, Tgfβ3) were almost two-
fold upregulated, indicating increased Hif1α signaling. Moreover, increased 
abundance of pro-inflammatory cytokines (TNF, Il-6 and Il-1β) was associated with 
2h isoflurane treatment and samples taken 6h after anesthesia (Wu et al., 2012). 
Furthermore, enhanced cytokine stimulation was associated with elevated levels of 
matrix metalloproteinases (MMP) (Qin et al., 2015). Therefore, transcriptional 
changes in cytokines and MMPs were investigated with the outcome of unaltered 
expression levels. However, western blot analysis or immunostainings might provide 
further insight in possible changes of cytokines and MMPs in our treated animals.  
Together, the increase of Hif1α signaling after long-term isoflurane treatment is in 
accordance with published data (Chai et al., 2016; Zhao et al., 2014). The postulated 
mechanism of isoflurane BBB manipulation by Zhao and others, based on in vitro 
treated primary human brain vascular endothelial cells, comprised enhanced Hif1α 
stability, which triggers Vegfα and Tgfβ3 expression and this affects the expression 
of the tight junction protein, occludin (Ocln) (Zhao et al., 2014). Our data are in 
agreement with the increase of Hif1α signaling, but the effect on occludin expression 
was not detectable. Instead, our results of in vivo long-term isoflurane treatment 
demonstrated decreased occludin and claudin-5 protein abundance and further 
increased claudin-5 expression.  
Since long-term isoflurane treatment has been investigated previously, we focused 
on the short-term treatment. For the first time, we showed BBB manipulation by 
isoflurane treatment already after 30 min. Therefore, we wanted to investigate 
whether the mechanism of BBB opening might be comparable to long-term 
treatment. Short-term isoflurane treatment revealed decreased abundance of tight 
junction proteins occludin and claudin-5. Changes in expression levels were not 
detected for tight junction proteins. Furthermore, short-term isoflurane treatment in 
contrast to long-term treatment showed unaltered expression levels of Hif1α 
signaling components. The induced BBB manipulation of short-term isoflurane 
treatment was further independent of expression of pro-inflammatory cytokines and 
MMPs. In summary, these results suggest a different mechanism of BBB 
manipulation for the short-term isoflurane treatment compared to long-term 
treatment. Furthermore, one possible mechanism of short-term isoflurane treatment 




5.3.2.1 Short-term BBB manipulation by isoflurane functions via TJ 
internalization? 
The complex structure of tight junction proteins at the intercellular cleft allows highly 
dynamic adaptation to various extracellular stimuli. To date two mechanisms of tight 
junction remodeling are postulated, which include diffusion and endocytosis 
(Stamatovic et al., 2017). Highly dynamic diffusion of the tight junction proteins 
occludin and ZO-1 was shown by FRAP and FLIP experiments with the use of an 
epithelial cell line (Fluorescence recovery after photobleaching and Fluorescence 
loss in photobleaching) (Shen et al., 2008). Since protein abundance of occludin and 
claudin-5 was highly diminished after isoflurane treatment, internalization of tight 
junction proteins most likely functions via another mechanism e.g. endocytosis.  
The endocytosis of tight junction proteins is a well characterized mechanism in health 
and disease (Stamatovic et al., 2017). In fact, it has been shown that occludin is 
internalized via caveolin-1-dependent mechanism upon TNFα signaling (Marchiando 
et al., 2010). Furthermore, the chemokine CCL2 was able to induce internalization of 
occludin and claudin-5 mediated via lipid raft/caveolin-1 endocytosis (Stamatovic et 
al., 2009). Additionally, internalized tight junction proteins were found in early and 
recycling endosomes until they were re-shuttled to the cell membrane.  
Occludin as well as claudin-5 were highly prone to phosphorylation by Rho kinase 
(Yamamoto et al., 2008). Moreover, only highly phosphorylated occludin was found 
to build up tight junction structures, whereas non- or less phosphorylated occludin 
localized at the basolateral membrane and in cytoplasmic vesicles (Sakakibara et 
al., 1997). Furthermore, occludin phosphorylation by different isoforms of protein 
kinase C (PKC) was shown to be important for the binding to the adaptor protein ZO-
1 (Rao, 2009). Moreover, volatile anesthetic agents like isoflurane and sevoflurane 
were shown to be involved in Rho kinase function (Hanazaki et al., 2008; Kim et al., 
2014; Yang et al., 2016) and PKC activity (Turner et al., 2005; Zhong et al., 2002). 
In fact, isoflurane functions via the PI3 kinase pathway to inhibit Rho kinase 
phosphorylation of myosin light chain kinase in rat bronchial smooth muscles (Yang 
et al., 2016). 
Therefore, one hypothesis of isoflurane function of tight junction internalization might 
be that kinase activity (e.g. Rho kinase) is inhibited by isoflurane, which leads to 




In more detail, isoflurane anesthesia leads to the rapid exposure of isoflurane to 
endothelial cells. Isoflurane might induce alterations of Rho kinase activity, which 
leads to modifications of the phosphorylation status of tight junction proteins e.g. 
occludin and claudin-5. At least for occludin it has been shown that changes in the 
phosphorylation state are detrimental for tight junction localization (Sakakibara et al., 
1997). Occludin, claudin-5 and ZO-1 are able to be internalized either by caveolae 
or clathrin-induced vesicle endocytosis (Stamatovic et al., 2017). Furthermore, 
internalized occludin and claudin-5 are stored in endosomes and are able to be 
recycled back to the plasma membrane upon so far unknown stimuli (Stamatovic et 
al., 2009). This predicted mechanism might be suitable to explain our temporarily 
confined BBB manipulation by short-term isoflurane treatment. Nevertheless, direct 
evidence of the involvement of Rho kinase activity needs to be elucidated in the near 
future. Therefore, analysis of the phosphorylation state of occludin and claudin-5 as 
well as analysis of Rho kinase abundance and activity needs to be performed.  
 
 
Figure 5.11I Theoretical mechanism of isoflurane-induced tight junction internalization. a) 
In endothelial cells the tight junction proteins occludin and claudin-5 are linked to the actin 
cytoskeleton via adaptor molecules such as ZO-1. Kinases such as RhoK phosphorylate tight 
junction proteins, which serves as a prerequisite for their localization in the intercellular cleft. b) 
Short-term isoflurane treatment might inhibit Rho kinase activity, thereby probably inducing the 
internalization of occludin and claudin-5 via caveolae or clathrin-coated vesicles. Further ZO-1 
redistribution might be possible.  
 
5.3.3 Benefit of isoflurane-induced BBB manipulation for glioblastoma 
treatment 
The present work summarizes the investigation of isoflurane anesthesia as a tool to 
modulate BBB permeability and further to enhance drug delivery in a glioblastoma 
mouse model. Previously, it has been reported that the tumor core formed by 




2014). In our Gl261 implanted mice, we showed that short-term isoflurane treatment 
increased Evans blue entry from the tumor core into the whole brain tissue. 
Furthermore, Evans blue application after isoflurane withdrawal revealed unaltered 
BBB permeability. These findings suggested that short-term isoflurane treatment 
serves as a suitable tool to enhance the delivery of chemotherapeutic agent in a 
temporarily confined manner into the brain tissue of tumor implanted mice. 
In a first therapeutic approach we treated glioblastoma implanted mice with a 
combined treatment of short-term isoflurane anesthesia after intravenous injection of 
the non-permeable cytostatic agent cisplatin. The results after 14 days revealed, 
decreased tumor volume, increased T-cell numbers in the tumor surrounding and 
reduced tumor cell viability. The most remarkable finding was the reduction of 
migrating tumor cells and therefore the decreased potential of tumor cells to spread 
into healthy brain tissue.  
Already several decades ago, mechanisms to manipulate BBB function have been 
investigated including osmotic disruption and the neurovascular mediator bradykinin 
(Matsukado et al., 1996; Siegal et al., 2000). These early attempts developed several 
disadvantages such as the invasive and long-lasting disruption of the BBB, which 
induced several undesired side effects. In recent years, several systems to 
manipulate BBB function by a non-invasive method were under investigation with 
highly improved outcome. These systems include synthetically modified E-cadherin 
peptide (On et al., 2017, 2014), application of a focused ultrasound (Liu et al., 2014; 
Wei et al., 2013), NMDA activation via high-intensity magnetic stimulation (Vazana 
et al., 2016) and the development of highly specific nanoparticles (Lee, 2017) (see 
chapter 5.1.1.5).  
The use of isoflurane anesthesia for the manipulation of BBB function in a defined 
period to increase the entry of chemotherapeutic agents into brain tissue of 
glioblastoma patients provides a promising perspective for future clinical trials. One 
major advantage of isoflurane anesthesia is that our used set-up of 2.5% isoflurane 
is considered a clinically relevant concentration (Zhao et al., 2013) and clinical 
application has already been approved. Moreover, the application of isoflurane for 
the duration of 30min seems to be safe and BBB manipulation most likely reversible. 
Chemotherapy for glioblastoma patients can be applied via intravenous infusions in 
combination with short-term isoflurane anesthesia under medical supervision with 














The used laboratory expendable material and equipment, if not mentioned differently, 
was provided by BD Falcon (Heidelberg, Germany), Bio-rad (München, Germany) 
Gilson (Limburg-Offheim, Germany), Eppendorf (Hamburg, Germany), Sartorius 
(Göttingen, Germany) and Greiner Bio-One (Frickenhausen, Germany). 
6.1 Equipment 
Treatment  
Freestyle Precision System Abbott Diabetes Care 
Mouse restrainer In-house made 
 
Molecular Biology  
7500 Fast Real-Time PCR System Applied Biosystems 
PowerPac 300 Power Supply Bio-Rad 
SDS-PAGE gel casting and running units Bio-Rad 
Eon Microplate Spectrophotometer BioTek 
Table-top ThermoMixer Eppendorf 
Table-top Centrifuge Heraeus Sepatech 
INTAS ChemoCam Imager ECL HR-16-3200 Intas 
INTAS UV-system with Camera and printer Intas 
PCR-machine PeqLab 
NanoDrop200 Spectrophotometer Thermo Scientific 
Homogenizer Ultra Turrax T8 Kinematica 
Lyophilization LMC-1 BETA 1-16 Christ 
 
Tissue Culture  
Clean bench Heraeus 
Cooling centrifuge Optima TLX Beckmann 
Incubator Heraeus 
 
Tissue Preparation  
Student vannas spring scissor  Fine Science Tools 




Standard scissor Fine Science Tools 
Dumont forceps Fine Science Tools 
Scalpel blades (#21) Fine Science Tools 
Scalpel handel Fine Science Tools 




Isoflurane anesthesia station Isotek5 Groppler 
Animal temperature control ATC1000 WPI World Precision 
Instruments 
Microscope M76 Leica 
OP lamp KL1500 compact Schott 
Omni Drill 35 WPI World Precision 
Instruments 
Injection needle 5A-FN-GP 5µl S.G.E. Analytic Science 
Scissor (11-755-11-07) KLS MARTIN 
Ball Mill, Carbide 501853 WPI World Precision 
Instruments 
1x Histoacryl (tissue glue) Braun 





Leica Jung Cryocut CM3000 Leica 
Embedding station HMP110 Microm 
Paraffin embedding center  Microm 
Sliding microtome HM400 Microm 




Semi 35° diamond knife Diatome 
Ultra 45º diamond knife Diatome 
Heatplate Leica 








Axio Observer. Z1 Zeiss 
Axiophot Zeiss 
LEO EM 912AB electron microscope Zeiss 




Elevated beam test In-house made 




Adobe Illustrator CS5  
ImageJ  
Fiji  
GraphPad Prism 5  
Microsoft Excel 2013  
Zen 2012 Zeiss  
LSM software (Confocal images acquisition)  
Mendeley (Reference manager)  
Amira Software, Visage Imaging (MRI quantification)  
 
6.2 Expendable Materials 
All expendable material, if not mentioned differently, were purchased from Falcon 
(Becton Dickinson, Le Pont De Claix, France) and Eppendorf (Eppendorf, Hamburg, 
Germany). Culture flasks were obtained from Greiner Bio-One (Greiner Bio-One, 
Frickenhausen, Germany). 
 
Glucose test strips Abbott Diabetes Care 
Ketone test strips Abbott Diabetes Care 




pH reagent strips Macherey-Nagel 
Syringe 1 ml BD Bioscience 
Venofix® 0.4 x 10 mm Braun 
Cover glass Assistant 
HistoBond® slides Marienfeld 
Tissue cassettes Polyscience Inc. 
Copper grids Science Services 
PVDF-Membran Hybond-PTM Amersham 
Aqua-Poly/Mount Polysciences 
Eukitt Kindler 
Tissue-Tek® O.C.T. Compound VWR 
Skimmed milk powder Frema 
Eye ointment Bepanthen 
Formamide Sigma 
50ml Falcon filter BD Bioscience 
21-gauge cannula BD Bioscience 
23-gauge cannula BD Bioscience 
Cell culture flask Greiner Bio-One 
 
6.3 Chemicals 
All chemical, if not mentioned otherwise, are purchased from Merck KGaA 
(Darmstadt, Germany), Roche Diagnostics GmbH (Mannheim, Germany), Serva 
(Heidelberg, Germany) and Sigma-Aldrich GmbH (Munich, Germany).  
 
Isoflurane CP® CP-Pharma 
Cis-Platin (cis-Diamineplatinum(II)dichloride) Sigma-Aldrich Chemie 
GmbH 
Xylariem Ecuphar 










Dulbeco’s Modified Eagle’s Medium (DMEM) Gibco/ Invitrogen 
HBSS (Hanks balanced salt solution) Lonza 
Glucose Sigma-Aldrich Chemie GmbH 
Poly-L-lysine Sigma-Aldrich Chemie GmbH 
Insulin Sigma-Aldrich Chemie GmbH 
Horse serum Sigma-Aldrich Chemie GmbH 
EGTA 
(Ethylene-bis(oxyethylenenitrilo)tetraacetic acid) 
Sigma-Aldrich Chemie GmbH 
Penicillin/streptomycin Lonza 
GlutaMax™ Gibco/ Invitrogen 
Bovine serum albumin (BSA) Biomol GmbH 
 
6.4 Enzymes 
GoTaqTM DNS-Polymerase Promega 
Proteinase K (10mg/ml) Boehringer 
PhOSstop EASYstep phosphatase inhibitor Roche Diagnostics GmbH 
Complete Mini protease inhibitor Roche Diagnostics GmbH 
DNase Roche Diagnostics GmbH 
Papain Worthington Biochemical 
Corp. 
Trypsin Invitrogen 
Nucleotide (dATP, dCTP, dGTP, dTTP) Boehringer 
 
6.5 Kits 
DAB Zytomed Kit Zytomed Systems GmbH 
DC Protein Assay (Lowry) Bio-Rad 
LSAB2 kit Dako 
Vector Elite ABC Kit Vector Labs 
RNeasy Mini kit DNase Qiagen 




Western Lightning™ Plus-ECL Perkin Elmer Life Sciences, 
Inc. 
Superscript IIITM Kit Invitrogen 
Click-it™EdU Alexa Fluor™555 Imaging kit Thermo Fischer Scientific 
DeadEnd™ Colorimetric TUNEL System Promega Corporation 




LAMP1  1:200 IHC BD Biosciences 553792  
GFAP 1:200 IHC Novocastra NCL-GFAP-GA5 
MAC-3  1:400 IHC Pharmigen 01781D 
GFP 1:500 IHC Rockland 
APP 1:1000 IHC Chemicon 
CaII 1:200 IHC kindly provided by S. Ghandour PMID: 
118210 
Olig2 1:100 IHC kindly provided by J. Alberta, PMID: 
15198128 
CD3  1:50 IHC Serotec MCA1477  
Isolectin IB4 1:50 IHC Vector Lab 
Occludin 1:10 IHC Invitrogen 47-4400 
Claudin5 1:10 IHC Invitrogen #35-2500 
ZO-1 1:10 IHC Invitrogen #61-7300 
Plp1 1:100 IHC Jung et al., 1996  
TUNEL Kit Promega 




NG2 (AN2) 1:100 IHC kindly provided by J. Trotter, Mainz 
ATF6 1:500 WB  Abcam #40256 
Oxct1 1:1000 WB Proteintech Europe #12175-1AP 
Actin 1:2500 WB Sigma #A3853 
 
Secondary antibodies 
α-rabbit-HRP  1:5000 WB Dianova 
α-mouse-HRP  1:5000 WB  Dianova 
α-mouse-Alexa488  1:1000  ThermoScientific A-21202  
α-mouse-Alexa555  1:1000  ThermoScientific A-31570  
α-rabbit-Alexa488  1:1000  ThermoScientific A-21206  
α-rabbit-Alexa555  1:1000  ThermoScientific A-31572  
α-rat-Alexa488  1:1000  ThermoScientific A-21208  
 
6.7 Buffers and Solutions 
Fixation 
Avertin  
2% [w/v] 2,2,2 Tribromethanol 99%  
2% [v/v] Amylalkohol  
Mixed at 40°C for 30 min, filtered and stored at -20°C  
 
16% [w/v] Paraformaldehye (PFA) stock solution  
16% [w/v] Paraformaldehyde cooked at 65°C for 15 min while stirring  







0.2M Phosphate buffer (fixation buffer)  
0.36% [w/v] Sodiumdihydrogenphosphate (NaH2PO4)  
3.1% [w/v] di-Sodiumhydrogenphosphate (Na2HPO4)  
1% [w/v] Sodium chloride  
 
4% [v/v] Paraformaldehye (PFA) for immunohistochemistry  
4% [v/v] PFA  
0.1 M Phosphate buffer  
 
Karlsson-Schultz (K+S) fixative for electron microscopy  
4% [w/v] PFA  
2.5% [v/v] Glutaraldehyde  
0.1 M Phosphate buffer 
 
Molecular biology 
10 mM dNTP (50x stock)  
2.5 mM each nucleotide (dATP, dCTP, dGTP, dTTP) (Boehringer-Ingelheim)  
200 μM final concentration in a PCR reaction (50 μM each nucleotide)  
 
TBE 20x (stock solution)  
1.8 M TrisBase  
1.8 M Boric acid  
200 mM EDTA 
 
2 % agarose gel  
3.5 g agarose  










Protein lysis buffer  
1x TBS  
0.1% [v/v] SDS  
0.1% [v/v] Triton X-100  
Complete Mini protease inhibitor (Roche Diagnostics GmbH) and PhOSstop 
EASYstep phosphatase inhibitor (Roche Diagnostics GmbH) tablets were freshly 
added to the protein lysis buffer (1 tablet/10ml) before use. 
 
SDS separating gel (1.5 mm thickness)  
10% [v/v] Acrylamide / Bisacrylamide 29: 1  
0.4 M Tris-HCl pH 8.8  
0.1% [w/v] SDS  
0.03% [v/v] Ammonium persulfate  
0.08% [v/v] TEMED  
 
SDS stacking gel (1.5 mm thickness)  
4% [v/v] Acrylamide / Bisacrylamide 29: 1  
125 mM Tris-HCl pH 6.8  
0.1% [w/v] SDS  
0.05% [w/v] Ammonium persulfate  
0.1% [v/v] TEMED 
 
4x SDS sample buffer  
40% [v/v] Glycerol  
240 mM Tris/HCl pH 6.8  
8% [v/v] SDS  








10x SDS running buffer (Laemmli buffer)  
250 mM Tris base  
1.92 M Glycine  
1% [v/v] SDS 
 
Transfer buffer  
96 mM Tris base  
78 mM Glycine  
20% [v/v] Methanol 
 
10x Tris-buffered saline (TBS)  
500 mM Tris/HCl, pH 7.5  
1.5 M NaCl 
 
1x TBS with Tween-20 (TBST)  
50 mM Tris/HCl, pH 7.5  
150 mM NaCl  
0.05% [v/v] Tween-20  
 
Immunoblot blocking buffer  
5% [w/v] non-fat dry milk powder in 1x TBST  
 
Immunohistochemistry 
10x Phosphate buffered saline (PBS)  
1.7 M NaCl  
0.04 M KCl  
0.04 M Na2HPO4  
0.018 M KH2PO4  







0.01 M Citrate buffer (pH 6.0)  
1.8 mM Citric acid  
8.2 mM Sodium citrate  
Prepared freshly before use.  
 
BSA/PBS  
0.04 M NaH2PO4  
0.16 M Na2HPO4  
1.8% [w/v] NaCl  
1.0% [w/v] Bovine serum albumin (BSA)  
 
Tris buffer (pH 7.6)  
50 mM Tris/HCl, pH 7.6  
0.9% [w/v] NaCl  
Prepared freshly before usage.  
 
Mayer’s haematoxylin solution  
0.1% [w/v] Haematoxylin  
0.02% [w/v] NaIO3  
5% [w/v] K2Al2(SO4)4 ∙ 24H2O  
Added under constant shaking.  
5% [w/v] Chloral hydrate  
0.1% [w/v] Citric acid added  
Always filter freshly before usage.  
 
Scott’s solution  
0.2% [v/v] KHCO3  
2% [w/v] MgSO4  
 
HCl - alcohol  
0.09% [v/v] HCl  







171.3 g Glycidether 100  
115 g DDSA (Dodecenyl succinic anhydride)  
89 g MNA (Methyl nadic anhydride)  
Mixed for 10 min.  
6.5 ml DMP-30  
Added and mixed for another 20 min. 
 
Methylene blue/ azure II  
1% Na-tetraborat (Borax)  
1% Methylen blue  
1% Azure II  
Azure II and Methylene blue were freshly mixed 1:1 before use.  
 
Formvar solution  
1.25% [w/v] Formvar  
50 ml Chloroform  
Mixed for 30 min. Store protected from light at RT. 
 
Tissue culture 
Cultivation Media (Glioblastoma GL261-GFP) 
DMEM (4,5 g/l glucose, pyruvate) 
+ 10% FCS  
+ 1% GlutaMAX  






6.8 Marker, dyes and tracer 
GeneRuler 100 bp DNA ladder Thermo Fisher Scientific 
PageRuler™ Plus Prestained Protein Ladder Thermo Fisher Scientific 
DAPI (4,6-diamidino-2-phenylindol) Roche Diagnostics GmbH 


















































































































































































GL261 mouse glioma cells expressing green fluorescent protein (GPF) were kindly 














All animal experiments were performed in compliance with the animal policies of the 
Max Planck Institute of Experimental Medicine, and were approved by the German 
Federal State of Lower Saxony.  
In this study, we used C57BL/6N wildtype and Plp1 overexpressing transgenic mice, 
line 72 (PLP-tg72/72; Readhead et al., 1994). Mice were bred and kept in individually 
ventilated cages with a 12-hour day/night cycle. Mice were sacrificed by cervical 
dislocation or by perfusion after deep anesthesia with Avertin. Only male mice were 
used in both studies.  
 
7.1.1 Treatment 
PLP-tg72/72 mice were fed ad libitum a standard pellet chow (ssniff V1124) with or w/o 
supplemented cholesterol (5%), a medium chain fatty acid chow (ssniff MCT, 
modified Surwit) or a ketogenic chow (KD, ssniff E15249-30). Duration of feeding 
diets as indicated.  
For the classical ketogenic diet a specialized rearing device was applied (developed 
by Tim Düking). Maternal milk production is highly impaired in response to high fat 
diets (Sussman et al., 2013). Therefore, a plateau and a box with a small hole were 
installed to separate the chow of the pups and damns.  At around P15, the pups 
started to enter the installed box in which the ketogenic or standard chow was 
provided. In contrast, the medium chain fatty acid diet contained a sufficient level of 
carbohydrates (compared to KD), which are preferentially used to cover high energy 
expenditure during lactogenesis (Butte, 1999). Therefore, the standard cage set-up 
was used. Weight of the mice was monitored every week until twelve weeks of age 
starting with two weeks. Blood for glucose and β-hydroxybutyrate measurements 
were taken from mice tail tip weekly using the Freestyle Precision System with the 
corresponding glucose and ketone test strips (Abbott Diabetes Care). Endpoint 
serum pH was analyzed with reagent strips (Macherey-Nagel, Düren, Germany). 




capillary, Brand, Wertheim, Germany) from the eye vein. Samples were incubated at 




Eight weeks old male C57BL/6N mice were anesthetized with an intraperitoneally 
injection of ketamine/xylazine 85 mg per kg body weight/ and 7 mg per kg body 
weight respectively. The head of the mice was shaved and a small hole was drilled 
2mm lateral, 1mm anterior and 3 mm deep in the right hemisphere of mice. The mice 
were transferred into a stereotactic instrument (Kopf) and 5 µl PBS containing 
7.5x104 GL/261-GFP cells were injected. The wound was cleaned, sealed with tissue 
glue (Histoacryl) and 2-4mg/kg of the analgetic carprofen was injected 
subcutaneously. Respiration and body temperature was constantly monitored until 
the mice woke up and recovered from anesthesia. Mice were housed in individually 
ventilated single cages with a 12-hour day/night cycle. After two weeks mice were 
sacrificed by perfusion after deep anesthesia with Avertin. 
 
7.2.2 Treatment 
Mice were divided in four groups: cisplatin, cisplatin + isoflurane, saline and saline + 
isoflurane. At day eight and eleven after implantation mice were treated according to 
their group with 3mg/kg cisplatin (solution: 0.5mg/ml cisplatin in saline 0.9% NaCl) 
or equal amount of saline. Afterwards they were directly put into the isoflurane 
evaporator chamber (Isotek5, Groppler) preflushed with 4% of the volatile anesthetic 
isoflurane for 2min and then decreased for another 28min to 2% isoflurane at a flow 
rate of 0.7l/min. Body temperature and respiration was controlled (Animal 
temperature control ATC1000) during anesthesia and the mice were allowed to wake 
with 100% O2 for 2min at the end of isoflurane treatment. Due to nephrotoxic side 
effects of the cisplatin treatment mice got an i.p injection of 300µl saline before and 
after the treatment, and after 24h. A single i.p. injection of EdU was applied 16h 
before the mice were sacrificed. On day 14 after implantation mice were sacrificed 





7.3 Molecular biology 
7.3.1 Genotyping 
Tail or Ear biopsies were taken from PLP-tg72/72 mice and digested using the 
NucleoSpin®Tissue Kit (Macherey-Nagel) according to manufacturer’s instructions. 
The concentration of the DNA samples were measured with the NanoDrop200 





3-10 μl DNA (100ng)  
0.5 μl Primer (1751 NGII Primer)  
0.5 μl Primer (1750 NGII Primer)  
0.5 μl Primer (19398)  
0.5 μl Primer (19399)   
2 μl dNTP’s (2 mM)  
5 μl Go-Taq buffer (5x)  
0.1 μl Go-Taq  
 
Reaction batch was filled with ddH2O to a total volume of 20 µl and the PCR (Peqlab) 
reaction was started using the following program: 
 
PCR program:  
(1) 95°C 3 min  
(2) 56°C 30 sec  
(3) 72°C 40 sec   19x  
(4) 95°C 1 min  
(5) 56°C 1 min 





DNA fragments were visualized with the use of 5 μl GelRed (1:40.000) added to each 
PCR reaction. Samples were loaded on a 2% agarose gel and gel electrophoresis 
was done in a running chamber with 1x TBE buffer for 60-100 min at 120 V. 
GeneRuler 100 bp DNA ladder (Thermo Scientific) was used as a size marker. For 
detection the INTAS UV-system with Camera and printer (Intas) was used. 
Homozygote and heterozygote Plp-tg mice were distinguished by comparing the 
transgene band to NGII control bands. 
 
7.4 Gene expression analysis 
7.4.1 RNA purification 
RNA purification from brain tissue was done using the RNeasy kit (Qiagen) following 
manufacturer´s instructions. RNA quality and quantity was determined either on 
NanoDrop200 Spectraphotometer (Thermo Scientific) or Agilent 2100 Bioanalyzer 
(Agilent Technologies).  
 
7.4.2 Complementary DNA (cDNA) synthesis 
Reverse transcription (RT) was done using the SuperScript III (Thermo Fisher 
Scientific). 
 
First RNA was premixed with two different primer: 
4 μl RNA (0.4-1 μg)  
1 μl dT mix Primer (0.6 pmol/μl)  
1 μl N9 (random nonamers 120 pmol/μl)  
 
Then samples were incubated at 70°C for 2 minutes, put on ice and the following mix 
was added to the reaction:  
 
2 μl 5x first strand buffer  
0.5 μl dNTP (10 mM)  
1 μl DTT (100 mM)  





The reaction mix of 10.5 μl was centrifuged and the following PCR program was 
used: 
(1) 25ºC 10 min  
(2) 50ºC 45 min  
(3) 55ºC 45 min  
 
Synthesized cDNA was diluted with ddH2O to a final concentration of 0.5 ng/μl. 
 
7.4.3 Quantitative real-time PCR (qRT-PCR) 
Quantitative RT-PCRs were performed in triplicates with the GoTaq master mix 
(Promega) on the Roche LC480 Detection System (Applied Biosystems). Expression 
values were normalized to the geometric mean of the housekeeping genes, Hprt 
(Hypoxanthin-Phosphoribosyl-Transferase 1), Rplp0 (60S acidic ribosomal protein 
P), Rps13 (Ribosomal Protein S13) and analyzed by the ΔΔCt method. Obtained 
data of RT-PCR is calculated as the relative expression to controls. 
 
7.5 Protein biochemistry 
7.5.1 Sample preparation 
Mice were sacrificed by cervical dislocation and spinal cord samples were snap 
frozen in liquid nitrogen. Frozen spinal cord tissue was homogenized in 600µl 
sucrose buffer with the Ultraturrax (T8, Ika, Staufen, Germany) at highest settings for 
20-40 s. Lysates were centrifuged for 5min at 13.000 rpm to remove nuclei and the 
supernatants were used for protein biochemistry.   
 
7.5.2 Protein assay  
According to the Lowry method for the measurement of protein concentrations 
(LOWRY et al., 1951) the Bio-Rad DC Protein Assay kit was used following 




4µg/µl) were used to evaluate sample concentration. An Eon microplate 
spectrophotometer (BioTek) detected the absorbance at 650 nm and calculated the 
concentration according to standards.  
 
7.5.3 Protein separation using SDS-PAGE 
For the protein separation SDS-polyacrylamide gels with concentration of 12 % 
(MOPS Bis-Tris) and 1.5 mm thickness were used with the Bio-rad system. Samples 
were diluted in 2x SDS sample buffer and 5% 2-Mercaptoethanol or DTT was added 
for reducing conditions. Protein lysates were denaturated on a shaker for 10 min at 
40°C or 70° corresponding to the used antibody. In addition 5 μl of the marker 
(PageRuler™ Plus Prestained Protein Ladder) was loaded on the gel. According to 
manufacturer’s protokoll, the chamber of the Mini-PROTEAN® electrophoresis 
system (BIO-RAD) was filled with 1x SDS running buffer and the gel was run at 70 V 
and 50 mA for approximately 10 min. Then voltage was adjusted to 120 V and 25 
mA/per gel at RT for 1-2 h to separate proteins according to their size. 
 
7.5.4 Western blotting 
The semi-dry chamber (Invitrogen) was used for protein transfer. The PVDF 
membrane (polyvinylidene difluoride membrane (Hybond P, Biosciences, pore size 
0.45 μm)) was first activated for 1 min in 100% methanol. After washing two times 
with ddH2O the membrane was put in transfer buffer. The transfer system was 
assembled with three Whatman papers, activated PVDF membrane, protein gel followed 
by three more Whatman papers all pre-incubated in transfer buffer. Proteins were 
transferred at 20 V for 40 min. 
After blotting, the membrane was blocked with 5% milk powder in TBS-T (0.05% 
Tween-20 in TBS) at RT for 1 h. Membranes were incubated with primary antibodies 
(see chapter 6.6) in blocking solution on a rotor at 4°C overnight. On the next day 
membranes were washed three times for 10 min in TBS-T and detection with HRP-
conjugated secondary antibodies (1:5000 diluted in blocking solution) was done at 
RT on a rotor for 1h. Membranes were washed three times in TBS-T. TBS-T was 
removed from the membrane and 1 ml of Western-Lighting Plus-ECL Reagent 




bands with the Intas ChemoCam Imager for 1-15min. Obtained signals were 




7.6.1 Tissue preparation 
Mice were sacrificed by cervical dislocation and optic nerve, spinal cord and brain 
samples were immersion fixed in 4% paraformaldehyde (4% PFA, 0.1M Phosphate 
buffer, 0.5% NaCl) for 48h for immunohistochemistry. 
 
7.6.2 Paraffin embedding 
Fixed tissue was transferred to embedding cassettes and paraffin embedding was 
performed with a Tissue Processor (MICROM HMP 110).  
 
The following program was used:  
(1) 50% Ethanol   1 h  
(2) 70% Ethanol   2x 2 h  
(3) 96% Ethanol   2x 2 h  
(4) 100% Ethanol  2x 2 h  
(5) Isopropanol   1 h  
(6) Xylol    2x 2 h  
(7) Paraffin   2x 2 h  
 
Samples were transferred to metal forms and embedded in paraffin with the 
Embedding Station (MICROM AP 280). Paraffin blocks were stored at RT, cut in 5μm 
thick sections using the microtome (MICROM HM 400), mounted on slides and dried 





7.6.3 Histological and morphological analyses with DAB 
Paraffin was removed from the sections with the following protocol:  
(1) 60°C     10 min  
(2) Xylol     2x 10 min  
(3) Xylol/Isopropanol (1:1)  10 min  
(4) 100% Ethanol   5 min  
(5) 90% Ethanol   5 min  
(6) 70% Ethanol    5 min  
(7) 50% Ethanol    5 min  
(8) ddH2O    5 min 
 
Immunolabeling was performed as indicated (antibody list chapter 6.6) with either 
Dako- LSAB2 system (Dako) or Vector Elite ABC Kit (Vector Labs) following 
manufacturer’s protocol. For chromogenic staining, deparaffinized sections were 
incubated and cooked with citrate buffer in a microwave for 10 min. After a cooling 
phase of 20 min, the samples were incubated in Tris buffer containing 2% milk 
powder for 5 min. The slides were sealed with coverplates (Thermo Fisher Scientific) 
to ensure even distribution of solutions. The slides were washed again with Tris 
buffer containing milk powder and in the following blocked with goat serum in PBS 
(1:5) for 10 min. The primary antibody was diluted in PBS/BSA and incubated at 4°C 
overnight. On the next day slides were rinsed with Tris buffer containing 2% milk 
powder and directly incubate with either Dako- LSAB2 system or Vector Elite ABC 
Kit. Slides were then washed with Tris buffer and coverplates were removed. For 
detection, 3,3'-Diaminobenzidine was applied by using the DAB Zytomed Kit 
(Zytomed Systems GmbH) for 10 min incubation time. After DAB was washed off 
nuclear staining of the samples was performed by incubation in Haematoxylin 
(0.1%). Slides were dipped in HCl for 10 sec and Scott’s solution for 5 min.  
 
In the end the samples were dehydrated using the following protocol: 
(1) ddH2O    5 min 
(2) 50% Ethanol    5 min 
(3) 70% Ethanol    5 min  
(4) 90% Ethanol   5 min  




(6) Xylol/Isopropanol (1:1)  10 min  
(7) Xylol     2x 10 min  
 
Afterwards the slides were mounted with Eukitt (Kindler) and analyzed by light 
microscopy (Zeiss Axiophot Z1).  
 
7.6.4 Histological fluorescent analyses 
7.6.4.1 TUNEL/EdU Assay 
Paraffin was removed from the slides as described in chapter 7.6.3. The slides were 
rinsed with 0.85% NaCl for 5min followed by washing with PBS for 5min. 
Deparaffinized sections were post-fixed with 4% PFA for 15min and then washed 
twice with PBS. Slides were put in an opaque chamber filled with wet tissue paper 
and incubated with proteinase K (20µg/ml) for 10 min at RT. After washing with PBS 
the slides were again fixed with 4% PFA for 5min. The slides were rinsed with PBS 
and TUNEL Equilibration Buffer was incubated for 10min, followed by the incubation 
with the rTDT Reaction Mix. Afterwards the section were rinsed with saline-sodium 
citrate SSC and washed three times with PBS. To inactivate the endogenous 
peroxidase, 0.3% H2O2 was applied to the section and incubated for 5min. After three 
times washing with PBS, Streptavidin-488 (1:200) in PBS was applied for 30min at 
RT, followed by three washing steps. The sections were blocked two times with 3% 
HS in PBS for 10min and then the EdU click-it-cocktail was incubated for 30min at 
RT. Finally the sections were blocked again, incubated with nuclei staining (Dapi 
1:20000), washed with PBS and mounted with Aqua Poly Mount.  
 
7.7 Electron microscopy 
7.7.1 Tissue preparation 
Mice were sacrificed by cervical dislocation and optic nerve and spinal cord samples 
were immersion fixed in Karlsson-Schultz fixation (Schultz and Karlsson, 1965) (4% 






7.7.2 Epon embedding 
Region of interest of optic nerve and spinal cord samples was cut and stored, 
wrapped in a mesh, in baskets and put into the automated epon embedding machine 
(EMTP, Leica) running with the following protocol:  
 
(1) Phosphate buffer 3 x 10 min  
(2) 2% OsO4 4 hours  
(3) ddH2O 3 x 10 min  
(4) 30% Ethanol 20 min  
(5) 50% Ethanol 20 min  
(6) 70% Ethanol 20 min  
(7) 90% Ethanol 20 min  
(8) 100% Ethanol 4 x 10 min  
(9) Propylenoxid 3 x 10 min  
(10) Propylenoxid/Epon 2:1 2 hours  
(11) Propylenoxid/Epon 1:1 2 hours  
(12) Propylenoxid/Epon 1:2 4 hours  
(13) Epon 4 hours 
 
Afterwards samples were unwrapped, put into silicone moulds and polymerized in 
an oven at 60°C overnight.  
 
7.7.3 Preparation of semi- and ultra-thin sections 
For electron microscopic analyses, epon imbedded spinal cord was cut in semi-thin 
(0.5 mm) and ultra-thin (50-65nm) section on a microtome (Ultracut S, Leica) using 
a diamond knife (45°, Diatome).   
Semi-thin section were mounted on slides and stained with azur-II-methylenblue for 
1 min at 60°C. Ultra-thin sections were collected on formvar polyvinyl-coated copper 






7.7.4 Electron microscopy and analysis 
Pictures of uranyl acetate contrasted ultra-thin sections were taken with the LEO 
EM912AB electron microscope (Carl Zeiss NTS, Oberkochen, Germany) connected 
to an on-axis 2048x2048 CCD camera (Proscan, Scheuring, Germany).  
At least 12 pictures from the corticospinal tract of the spinal cord were taken. To 
randomize the quantification of myelin thickness, the grid tool of the Fiji software was 
used. G-ratio measurements were performed as described with the ratio of fiber 
diameter divided by axon diameter (Saher et al., 2012). Data of unmyelinated axons 
and g-ratio was obtained from 100 axons/per animal. Mitochondrial thickness was 
measured for 100 randomly chosen mitochondria/per animal.  
 
7.8 Blood-brain barrier permeability analysis 
Evans blue solution (1%,0.5 μg/ g body weight; Sigma) was intravenously injected 
and allowed to circulate for four hours. Mice were anesthetized with avertin 
intraperitoneally (0.2 ml per 10g body weight) followed by perfusion for 15 min at 2.5 
ml/min with 1x phosphate buffered saline. Brain samples (excluding brain stem and 
olfactory bulbs) were rinsed with PBS and cut sagittally. Hemispheres were frozen 
on dry ice and lyophilisated (Christ LMC-1 BETA 1-16) at -36 °C for 24 h under 
vacuum of 0.2 mBar. Evans blue was extracted from brain samples in 10 μl 
formamide (Sigma) per mg brain at 57°C for 24 h. Quantification of Evans blue 
fluorescence was done in triplicates on a fluorescent microscope (Observer Z2, 
Zeiss) connected with an AxioCam MRc3, x1 Camera Adaptor and the ZEN 2012 
blue edition software recorded at x10 magnification. The concentration of Evans blue 





7.9 Tissue culture 
7.9.1 Thawing and cultivation of GL261-GFP cells 
Frozen cryovials containing GL261-GFP cells in DMEM (+20% FCS +10% DMSO) 
were removed from the liquid nitrogen tank, thawed in the water bath at 37°C and 
then mixed with fresh media in a PLL-coated 75cm2 flask. The cells were allowed to 
attach and further cultivated in the incubator at 37°C and 5% CO2. Twice a week cells 
were washed with PBS, trypsinated and centrifuged at 800rpm for 10min. For 
implantation cells were counted and resuspended in PBS (75000 cells/5µl) and for 
keeping them in culture resuspended in media.  
 
7.9.2 Cayman’s WST1-Assay 
Cayman’s WST1 assay serves as a tool to analyze cell proliferation and therefore 
cell viability. The assay is based on the fact that tetrazolium salt WST-1 is cleaved 
by cellular mitochondrial dehydrogenases to formazan, which can only occur in living 
cells.  
For this assay cells are plated in a 96-well plate in a density of 104-105 cells per well 
dissolved in a volume of 100µl. Cultured cells were allowed to grow in an incubator 
at 37°C for 24 - 72h. The reagent mix was prepared by mixing equal amounts of 
Electron Mediator Solution and WST-1 Developer Reagent, which were both 
provided in the kit. Subsequently 10µl of the mix was added to each well and mixed 
gently on a shaker for one minute. Adherent cultures were incubated for 2h at 37°C 
and suspension cultures for 4h. Afterwards the 96-well plates were again shaked for 
one minute to ensure homogeneous mixture of the color. The absorbance was then 
measured in a plate reader at a wavelength of 450nm. 
 
7.9.3 Dose-response test: treatment of GL261 cells with cisplatin 
For the dose-response measurement of the GL261 cells with cisplatin, cells were 
cultivated as described in chapter 7.9.1. Plating was performed in a 96 well plate with 
104 cells per well. Media was changed every day. After 24h the plating density 




were treated with an increasing dose of cisplatin from 0.025 µg/ml up to 50 µg/ml 
dissolved in saline. WST-1 measurements (chapter 7.9.2) were performed after 24, 
48 and 72h. Adherent cultures (72h) were incubated in WST-1 reagent mix for 2h at 
37°C and suspension cultures (24h and 48h) for 4h. As positive control we used 
living cells dissolved in saline and as negative control we used cells with 2 mmol 
H2O2. 
 
7.10 Magnetic resonance imaging (MRI) 
Magnetic resonance imaging was performed in collaboration with Thomas Michaelis, 
Takashi Watanabe and Sabine Höfer from the Biomedizinische NMR Forschungs 
GmbH, Head Prof. Jens Frahm. Quantification on T1-weighted MRI was used to 
analyze tumor volume. Single images were analyzed, positive tumor area selected 
and tumor volume was quantified with Amira Software.  
 
7.11 Behavioral analyses 
7.11.1 Elevated beam test 
Motor coordination was assessed with the elevated beam test (in-house made, MPI 
of experimental medicine) every other week starting with 6 weeks of age. Mice were 
put on a beam (width 1.5 cm) and allowed to run toward a hiding box (Figure 7.1). 
The number of slips in a defined 55 cm distance was assessed as a mean of two 
best of three repeats per time point. 
 
 





Motor performance and balance were weekly measured with the rotarod (in-house 
made, MPI of experimental medicine, 3cm diameter) starting with two weeks of age 
(Figure 7.2). Mice were placed on the rotarod starting with a speed of 4 rpm. Speed 
was increased with 10 rpm/min until 26 rpm was reached and held for 10sec. Trial 
was complete after 150sec and the latency to fall was recorded. 
 
 
Figure 7.2| Rotarod 
7.12 Statistical evaluation 
Values are expressed as mean. All error bars show s.e.m. Statistical significance 
was calculated as indicated in figure legends by either one or two-way ANOVA or 
Student’s t-test of two-tailed uncoupled samples, and P-values are shown as *, 
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